












Faculty of Health Sciences 
Department of Community Medicine 
Self-reported musculoskeletal complaints  
Prevalence, risk factors, and mortality.  
The Tromsø Study. 
— 
Ole Fredrik Linnemann Andorsen 





What is this thesis about? 
Based on data from the Tromsø Study, this thesis describes some key issues regarding the 
epidemiology of longstanding musculoskeletal complaints (MSCs). Firstly, it provides estimates on 
how common MSCs are in a general population (including those who never seek medical advice for 
their MSCs). It further describes the distribution of MSCs by severity and by the characteristics of 
those who suffer from MSCs. The thesis also provides insight on health factors (both modifiable and 
non-modifiable) that may predict presence of MSCs later in life. The thesis elaborates consequences of 
longstanding MSCs, which have not been well described. Although pain and stiffness in the 
musculoskeletal system can have a great impact on daily life, such as the ability to continue working, 
it does not increase individual mortality risk. In sum, the thesis increases our understanding of MSCs 
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1 Norsk sammendrag 
Denne doktorgraden er basert på data fra den befolkningsbaserte Tromsøundersøkelsen. Over 
40 000 av Tromsø kommunes innbyggere har deltatt på minst en av de sju 
Tromsøundersøkelsene (Tromsø 1-7) i tidsrommet 1974 til 2016. Muskelskjelettplager ble 
definert som smerte og/eller stivhet i muskler og ledd som har vedvart i minst 3 måneder det 
foregående året. Den første studien var designet som en tverrsnittsstudie hvor data fra den 
sjette Tromsøundersøkelsen (2007/08) ble benyttet. I Tromsø 6 hadde 8,439 (42.7%) av de 
19,762 inviterte fylt ut spørreskjemaet om muskelskjelettplager fullstendig, og av disse var 
det 15.8% (kvinner: 19.4%, menn: 12.1%) som rapporterte å være sterkt plaget av 
muskelskjelettplager fra en eller flere kroppsregioner. Når milde og sterke plager ble sett 
under ett, hadde mer enn halvparten av deltakerne muskelskjelettplager fra minst en 
kroppsregion. Av disse var det nesten tre fjerdedeler som hadde plager fra to eller flere 
kroppsregioner. Dette tyder på at det er mer vanlig å ha en form for muskelskjelettplager enn 
ingen slike plager. Ofte ble kjente risikofaktorer for dårlig helse funnet hos deltakerne som 
rapporterte muskelskjelettplager. Den andre studien var en prospektiv kohortstudie hvis 
målsetning var å undersøke risikofaktorer for å utvikle muskelskjelettplager. Studien var 
basert på henholdsvis Tromsø 4 (1994/95) og Tromsø 6 (2007/08). Fordelen med dette 
studiedesignet er at man med større sikkerhet kan avgjøre om den enkelte risikofaktor har 
vært tilstede forut for muskelskjelettplagene. Flere av resultatene i den første studien ble også 
underbygget av resultatene fra denne studien. Dårlig selvopplevd helse, tobakksrøyking og 
lavt utdanningsnivå hos deltakerne predikerte tilstedeværelse av muskelskjelettplager 13 år 
senere. Selv-rapportert fysisk aktivitetsnivå predikerte ikke muskelskjelettplager etter at 
analysene var justert for andre risikofaktorer. Psykiske plager (angst/depresjon) var en viktig 
prediktiv faktor for muskelskjelettplager hos menn. Ingen av de undersøkte risikofaktorene 
ble funnet å øke kvinners risiko for muskelskjelettplager mer enn menns. I tråd med tidligere 
forskning på området viser denne doktorgraden at flere helsefaktorer bør evalueres når man 
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har med muskelskjelettplager å gjøre. Dette gjelder i klinisk sammenheng så vel som i 
forskningssammenheng. Resultatene fra den tredje studien gav ingen holdepunkter for at 
deltakere med muskelskjelettplager har høyere dødelighet sammenlignet med deltakere uten 
slike plager. Studien var basert på data fra den fjerde Tromsøundersøkelsen og data fra 
folkeregisteret og dødsårsaksregisteret og hadde en oppfølgingstid på 18-21 år. I fremtidig 
forskning vil det være interessant å studere den relativt store andelen av befolkningen som 
ved gjentatte undersøkelser rapporterer fravær av muskelskjelettplager. Det vil også være 
interessant å undersøke om deltakere gir konsistente svar selv om de får spørsmål om 




2 Summary in English 
This thesis used data from the large-scale population-based Tromsø Study. More than 45,000 
inhabitants of the municipality of Tromsø participated in at least one of the seven surveys 
conducted between 1974 and 2016 (Tromsø 1-7). In the papers constituting this thesis, 
musculoskeletal complaints (MSCs) were defined as having pain and/or stiffness in muscles 
and joints lasting for at least 3 months the previous year. In the Tromsø 6 survey (2007/08), 
8,439 (42.7%) of the 19,762 invitees provided a complete questionnaire on MSCs and were 
included in the analyses. In Paper I, which employed a cross-sectional study design and utilised 
data from the Tromsø 6 survey, 15.8% (women: 19.4%, men: 12.1%) of participants reported 
severe MSCs at one or more of the six body regions specified in the questionnaire. More than 
half of the 8,439 participants reported at least one MSC. Among those, nearly three-quarters 
reported MSCs in more than two body regions, which is in accordance with previous research. 
Hence, it is more common to report at least one MSC than no MSCs at all. Participants who 
reported MSCs were more likely to report coexisting negative health factors than participants 
without MSCs. Paper II had a prospective study design and investigated risk factors for MSCs 
utilising data from both the Tromsø 4 (1994/95) and Tromsø 6 surveys. Several of the 
associations revealed in Paper I showed evidence of temporality (i.e. a predictor present before 
the end-point) in Paper II, which is one of several criteria of causality. In accordance with 
previous research, poor self-reported general health status, tobacco smoking, and low 
educational level were predictors of MSCs. Physical inactivity did not predict subsequent 
MSCs 13 years later, after adjusting for other factors. Mental distress (i.e. depression and/or 
anxiety) was only a predictor of MSCs among men, doubling the odds of MSCs. None of the 
risk factors we investigated increased women’s risk of MSCs more than men’s, and could not 
explain the higher prevalence of MSCs among women. The present thesis demonstrated that 
modifiable and non-modifiable risk factors are important to consider when dealing with MSCs 
in both clinical and research settings. Finally, presence of MSCs did not increase mortality risk 
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in the general population of Tromsø (Tromsø 4 survey, 1994/95) during an 18-21-year period 
(Paper III). In the future, it would be of great value to explore protective factors among the 
relatively large part of the general population that seemed to be free of MSCs throughout 
different surveys and to examine if people respond differently to differently worded questions 
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4 Abbreviations 
ACR American College of Rheumatology 
BMI Body mass index 
CI Confidence interval 
CONOR-MHI  Cohort of Norway Mental Health Index 
GP General practitioner 
HUNT The Nord-Trøndelag Health Study 
HR Hazard ratio 
HSCL-10 Hopkins Symptom Checklist – 10 item version 
ICD-9 International Classification of Diseases, 9th Revision 
ICD-10 International Classification of Diseases, 10th Revision 
MSCs Musculoskeletal complaints 
OR Odds ratio 
Q1 First questionnaire in a survey of The Tromsø study 
Q2 Second questionnaire in a survey of The Tromsø Study 




In Norway, general practitioners (GPs) have an important role as gatekeepers in the national 
health and social welfare system. Since 2001, inhabitants of Norway have been entitled to a 
regular GP (fastlege). This contributes to continuity in the GP-patient relationship, and allows 
patients to discuss their health complaints and worries with the same GP throughout different 
settings, at least theoretically [1]. It has been reported that only 13.7% (range 4-28%) of 
consultations with GPs in Norway lead to referral to secondary care [2], meaning that many of 
the issues discussed in consultations with GPs in Norway are actually dealt with in a primary 
health care setting. Moreover, it has been estimated that 60-74% of symptoms reported in 
primary care settings cannot be explained by any specific pathology [3, 4]. Taking this into 
account, clarifying symptoms and solving cases in primary care are time-effective for the 
patient and the GP, as well as cost-effective for the community.  
A large portion of patients seeking primary care present to GPs with musculoskeletal 
symptoms and complaints [5, 6]. MSCs represent an important public health issue and are a 
common and costly health problem in the Western world due to their impact on disability and 
sickness absence from work [7]. Longstanding or recurrent musculoskeletal complaints 
(MSCs) can have a number of aetiologies, such as neurological conditions, systemic diseases, 
or mechanical injury. However, many MSCs remain unexplained after medical examination. 
We must be especially aware of this group of patients, as they often experience dissatisfaction 
after consultations, which could in itself, result in a delay in the improvement of symptoms 
[8]. The high number of patients with MSCs in primary care and the uncertainty regarding 
possible underlying causes, which range from self-limiting conditions to chronic diseases that 
could benefit from specific treatment, make diagnosis and treatment challenging even for 
experienced GPs. For all of the reasons outlined above, a closer investigation of what 
constitutes normal variations in MSCs are warranted if GPs are to distinguish those cases that 
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require more specialised diagnostic processes from those who do not. Improving the 
knowledge of the nature and possible implications of MSCs, and how to prevent them, will 
enhance the handling of this group of patients in primary care settings [9].  
5.1 Diseases of the musculoskeletal system 
Symptoms and illness represent an individual’s personal experience of being unwell, in 
contrast to diseases, which are more or less defined pathophysiological processes [10]. There 
is a large number of specific diseases and structural defects within the musculoskeletal system 
that could lead to longstanding MSCs. Only a few diseases are mentioned here in order to 
illustrate the large discrepancy between the prevalence of MSCs and the prevalence of 
biomedically verified diseases. Rheumatoid arthritis and ankylosing spondylitis are among the 
most prevalent inflammatory joints diseases. The prevalence of established rheumatoid 
arthritis in Norway is about 0.5%, i.e., about 25,000 patients, and the prevalence of 
rheumatoid arthritis is three times higher in women than in men. The corresponding figures 
for ankylosing spondylitis are about the same, except that men are more often affected than 
women [11], indicating that rheumatologic diseases account for a very small portion of MSCs 
in primary care. In the neurological field, the annual incidence of lumbosacral radiculopathy 
(low back pain with radiation to the leg) due to a herniated intervertebral disc has been 
reported to be 1-2% [12]. In Finland, the lifetime prevalence is higher in men than in women 
(5.3% versus 3.7%) [13]. Thus, prolapsed intervertebral discs only explain a small part of low 
back pain, which is reported to be one of the most common body regions for MSCs in the 
general population [14, 15]. In sum, the literature supports that only a small fraction of 
patients with MSCs is referred to specialised treatment. Consequently, primary care providers 
are responsible for diagnosing, treating, and following up the vast majority of patients 
presenting with MSCs.  
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5.2 Definition of musculoskeletal complaints in research 
Several different definitions of MSCs have been used in the literature. Many of them are 
based on questionnaires derived from the Standardized Nordic Questionnaire (SNQ) of 
musculoskeletal symptoms, developed by Kuorinka and colleagues [16]. As MSCs are by 
definition subjective, it is difficult to speak about a gold standard by which these self-reported 
measures can be validated, but questionnaires derived from the SNQ have been found to be 
useful for the surveillance of MSCs [15, 17, 18]. More comprehensive questionnaires derived 
from the SNQ include information on the specific character and/or duration of symptoms. 
Differences in the definition of MSCs in the literature have implications in the interpretation 
of results [19], as well as the comparability between studies. Some studies require a certain, 
widespread bodily distribution or even negative consequences in daily life before a symptom 
can be classified as MSCs [20]. The American College of Rheumatology’s definition of 
widespread MSCs (pain above the waist, below the waist, axial skeleton, and both sides of the 
body) from 1990 [21] has been used in several studies [22], increasing the comparability 
between studies that explore the epidemiology of multiregional MSCs.  
5.3 Symptoms in primary care 
This thesis has a general population perspective and aims to increase knowledge about MSCs 
that can be useful also for primary care providers. During the research process it has become 
clear that we need to underline the fact that our aim is to explore symptoms related to the 
musculoskeletal system, not musculoskeletal diseases. The international organisation for GPs 
and family physicians defines symptoms as “…any expression of disturbed function or 
structure of the body and mind by a patient. Cough, pain and tiredness are symptoms” [23]. 
Including “patient” in the definition implies that a complaint or sensation has elicited contact 
with a health professional. Indeed, symptoms are often the opener to the diagnostic process in 
primary care [8], and as stated above, only a small fraction of the symptoms represent 
diseases that require referral [24]. Knowledge on health complaints in the general population 
 
10 
is important as it helps GPs better take care of patients seeking primary care, and it can also 
help assess vulnerability to future symptoms and disease [25].  
Professor emeritus Knut Holtedahl, MD, has dedicated his career as a GP and a researcher to 
exploring the symptoms of cancer with which patients present to GPs. In his book, Early 
diagnosis of cancer in general practice, he describes the quantitative approach to diagnostic 
thinking in general practice: according to Bayes’ formula, positive predictive values (i.e. the 
frequency of disease among those reporting a symptom) can be calculated if the probability of 
the disease (i.e. prevalence of disease in the primary care setting), the probability of the 
symptom in the same population, and the probability that the symptom indicates disease are 
known [26]. Implementing this approach to diagnostic thinking for musculoskeletal 
symptoms is also possible, and taking into account the high number of primary care visits due 
to these symptoms, this approach could enhance GPs’ decision-making. As such, establishing 
the prevalence of MSCs in the general population would contribute greatly to improving the 
diagnostic process in primary care in Norway and in other countries where GPs have the role 
of gatekeeper in their health care and social systems. Furthermore, a population-based 
approach is suitable to develop knowledge on the prevention of chronic disorders, as it 
provides researchers the opportunity to study symptoms and associated health factors that 
occur in a population unsorted by health professionals. In the context of primary care, it is of 
utmost importance with research conducted in the general population, as this can describe 
symptoms, including MSCs, that exist outside of or prior to a visit to the GP’s office. In 
clinical settings, it is important to remember that individuals have a selection of symptoms 
and complaints that led them to seek health care, making primary care patients a relatively 




Several population-based health studies have been established in Norway during the last half 
century, and many of them have been repeated several times, providing a valuable source of 
health information for researchers and clinicians. The Nord-Trøndelag Health Study (HUNT) 
carried out in the middle part of Norway is the largest of its kind in the country. It contains 
information on overall health as well as musculoskeletal health [28]. The Ullensaker Study 
and The Hordaland Health Studies are population-based studies including data on 
musculoskeletal health. They are large-scale studies with several thousand participants each, 
and the questionnaires from these studies are similar to those used in many other surveys 
conducted in the same time period, including information on MSCs [29, 30].  The Tromsø 
Study [31], the Nordland Health Study (1988/89) [32], and the Bardu Musculoskeletal Study 
(1989/90) have provided information on musculoskeletal health from Northern Norway [33]. 
The reported prevalence of MSCs ranges from 17.1-78.6% in studies from various countries 
[34-42]; however, geographical and demographical differences between study populations 
may influence the figures. As stated above, variation in reported prevalence can also be 
explained by differences in the definition, duration, and localisation of MSCs. A strict 
definition of MSCs should theoretically give a lower prevalence than a wide definition [20]. 
Previous research has, to a large extent, focused on specific pain distribution, such as low 
back or upper limb, thus limiting the clinical applicability for GPs because many patients 
experience MSCs from multiple body regions [43-45]. To assure good clinical applicability of 
epidemiological studies on MSCs, it is important to present results both for all body regions 
combined and for each body region separately.  
Variations in prevalence may also reflect a true difference in the burden of MSCs between 
cohorts. In a Dutch general population, Wijnhoven and colleagues found that MSCs (lasting 
at least 3 months) were reported by a large number of participants (women: 45.1%, men: 
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39.3%) [14]. Whereas, Rustøen and colleagues reported a lower total prevalence (24.4%) 
when applying a similar definition to a Norwegian general population [46]. Hagen and 
colleagues reported that the prevalence of MSCs increased between two waves of the 
population-based HUNT Study [15]. Similar results were also reported in a Spanish 
population-based study [47], indicating that time trends may play an important role in the 
prevalence of MSCs. In sum, this underlines the importance of having prevalence information 
that is up to date and that such studies should be carried out in a context that assures local 
relevance. With this in mind, it is interesting to review the findings from two cross-sectional 
studies conducted by Hasvold and colleagues, which took place in two different Northern 
Norwegian communities at two different points in time (1986/87 and 1989/90) [48, 49]. The 
prevalence of headache and shoulder pain served as tracer-conditions of musculoskeletal 
illness in these populations and were very similar in these two surveys. In the Bardu 
Musculoskeletal Study, 7% of men and 11.5% of women reported weekly headache, while 
15.9% of men and 22.4% of women reported weekly neck and shoulder pain. By providing 
updated prevalence data on MSCs, the present thesis makes it possible to assess changes in 
the burden of MSCs over time in the Tromsø population. 
5.5 Gender  
A large body of evidence indicates that there is a higher prevalence of MSCs among women 
than men in general populations [14, 15, 34, 35, 38, 42, 46, 50, 51]. Even though the total 
prevalence was different, the gender difference in prevalence found in the Norwegian general 
population by Rustøen and colleagues (women: 27.6%, men: 23.3%) was similar to that found 
in a Dutch general population that applied the same definition of MSCs [14, 46]. Wijnhoven 
and colleagues further investigated the association between female gender and MSCs lasting 
at least 3 months by body region. They reported a significantly higher prevalence of MSCs at 
the neck, shoulder, wrist/hand, hip, and foot among women, with prevalence ratios ranging 
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from 1.42-2.16, while non-significant prevalence ratios were reported at the elbow, knee, 
ankle, and higher and lower back. In a highly selected Portuguese population receiving 
cardiac rehabilitation after acute coronary syndrome, 44% of the female participants reported 
MSCs, compared to only 24% of the male participants [52]. A recent study from Brazil 
reported that females in the younger parts of the population also reported more MSCs [53]. 
Kvalheim and colleagues found that early menarche was associated with the presence of 
widespread MSCs in a general female population, indicating that female hormonal factors 
could contribute to the risk of MSCs among women, but the contribution to the absolute risk 
of MSCs was small (3%) and did not fully explain the gender difference [54].  
A general practitioner from Sweden, Professor Eva Johanson, MD, thoroughly investigated 
the gender aspect of MSCs in her thesis Beyond frustration: understanding women with 
undefined musculoskeletal pain who consult primary care [55]. It underlines that health 
indicators and risk factors of MSCs are not always the same for women and men. It further 
points out that gender is not only a construct of genetic and biological components, but 
through complex mechanisms, also comprising social and structural components. These 
complex mechanisms may be lost when using a dichotomised gender variable in 
epidemiological research. However, as epidemiological studies are suitable for the 
examination of predictors or associated factors of different conditions, it is also possible to 
design studies to examine how specific demographic or lifestyle factors interact with each 
other to affect MSCs [56, 57]. As such, epidemiological studies are suitable to explore 
whether certain demographic, lifestyle, or socioeconomic factors show systematic, different 




5.6 Age  
There are many reasons why one would expect MSCs to be dependent on age. The 
physiological effects of aging, such as reduced elasticity of soft tissue [58], reduced joint 
function due to destruction of joint tissue [59], and changes in the skeleton [60], are factors 
that may contribute to increased risk of such complaints in older populations. However, 
several epidemiological studies have reported a peak in the prevalence of MSCs around 60 
years of age [15, 35, 38, 61], implying that other factors than aging are important. In Norway, 
people generally retire between 62 and 67 years of age. A lower prevalence of MSCs among 
those older than 60 years compared to the younger parts of the population could reflect 
reduced mental and physical stress after retirement [51]. Furthermore, an increase in the 
prevalence of MSCs has been reported in young age groups [15, 47], which is unlikely to be 
explained by aging and warrants further examination of the age distribution of MSCs. 
5.7 Tobacco smoking 
In the 1950s, nearly 70% of the male population and 25-30% of the female population in 
Norway were daily smokers. In 2013, the prevalence of daily smoking was much lower, with 
only 15% of men and 14% of women being daily smokers in Norway [62]. The prevalence of 
daily smoking has steadily decreased over the last 20 years, especially among the younger part 
of the population (Fig. 1) [63]. Tobacco smoking is an important and well-established risk 
factor for many diseases; it increases the risk of cardiovascular disease [64], lung cancer [65], 
and colorectal cancer [66]. The high incidence and mortality rates of lung and colorectal cancer, 
indicates that smoking alone is an important public health issue [67]. Moreover, a robust 
association between smoking habits and MSCs was found in a large cross-sectional study from 
Britain [68], and prospective cohort studies of Norwegian general populations have emphasised 
the higher risk of MSCs among smokers compared to non-smokers [56, 69]. Kvalheim and 
colleagues [56] found smoking to be a predictor of subsequent MSCs in a population free of 
MSCs at baseline. Overall, there is likely a multifaceted relationship between tobacco smoking 
 
15 
and MSCs. For instance, nicotine may have analgesic and relaxant effects that pull the 
associations in one direction, and the strong relationship between smoking and other negative 
health factors may present forces pulling in another direction. Furthermore, there are likely 
cohort effects, as the prevalence of smoking has strongly decreased the latest half century [56]. 
However, even a small increase in the risk of MSCs due to smoking may have large implications 
for public health, given the high prevalence estimates of MSCs in general. Still, the prevalence 
of tobacco smoking is high, and further investigation on how smoking predicts MSCs later in 
life could increase awareness and lead to smoking cessation and that could improve overall 
public health.  
 
Figure 1. Prevalence of daily smokers by age group and gender in Norway between 1996 and 2013. 
Source: Norwegian National Institute of Public Health [63]. 
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5.8 Physical activity and body mass index  
Both physical activity and body mass index (BMI) could be related to MSCs through 
proposed multifaceted pathways, involving mechanical, hormonal, metabolic, and emotional 
factors [70-73]. The Norwegian Directorate of Health recommends a minimum of 30 minutes 
of daily, moderate-to-intense physical activity [74]. Self-reported leisure time physical 
activity level corresponds to objectively measured activity level [75], and only one out of four 
men and women met the recommended level of activity. From a general health perspective, 
the favourable effects of physically activity are well-documented [76-78]. However, there is 
conflicting evidence on whether leisure time physical activity relates to the occurrence of 
MSCs in the general population [79-84], especially since it seems difficult to determine clear 
dose-response patterns in significant associations. Furthermore, it has been speculated that 
there may be a u-shaped relationship, in which those with a moderate physical activity level 
have less low back pain than their most sedentary or most active counterparts, but Heuch and 
colleagues could not establish such a relationship in their study [85]. A recently study showed 
evidence of joint effects between poor physical fitness and obesity in the development of 
MSCs [57]; thus, the relationship between MSCs and physical activity is likely to be 
complex.  
The association between high BMI and MSCs has been reported several times [70-73, 86]. 
Obesity is steadily increasing in the general population [87], and health professionals should 
be aware of the possible interactions and bidirectional relationships between physical activity 
and obesity on the development of MSCs. Both physical activity and high BMI can affect the 
mechanical exertion on the musculoskeletal system; it is likely that they interact and impact 
other negative health outcomes. With the conflicting evidence on the association behind 
physical activity and MSCs, and the assumed complex interaction with other health factors, a 
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thorough investigation is necessary to clarify if these modifiable lifestyle factors could be 
implemented in preventive health strategies to reduce MSCs in the population. 
5.9 Marital status  
Marital status has consistently correlated to different health outcomes [88], and these 
correlations have been particularly evident among men [89]. Robards and colleagues discussed 
several theories regarding this phenomenon. For example, healthier individuals could be 
selected to marriage, while their unmarried counterparts remain single, or are more frequently 
divorced or widowed. It may be that marriage itself provides a protective health effect through 
social and behavioural circumstances that unmarried individuals do not experience to the same 
degree. The association between marital status and MSCs is unclear. Indeed, not many studies 
have evaluated marital status as predictor of MSCs. A Spanish population-based study found 
that married men had an increased risk of MSCs compared to their single counterparts, while 
no such association was revealed among women [47]. However, other studies do not support 
these findings [34, 46]. Furthermore, it has been reported that low back pain predicted 
subsequent long-term work disability, but there were no differences across marital status [90].  
In 2015, the number of new marriages in Norway was 22,738 and the number of divorces was 
9,306 [91]. These figures have been relatively stable in the last 20 years (Fig. 2). Nevertheless, 
the high annual incidence of divorce in Norway may be a possible source of bias in 
prospectively designed cohort studies because a large proportion of participants that are married 
at baseline are likely to change their marital status, which dilutes the possible protective effect 
of marriage on MSCs. However, the results of cross-sectional studies, in which MSCs and 
marital status are measured at the same time or very close in time, are less vulnerable to the 
high incidence of divorce. 
18 
Figure 2. Annual incidence of marriage, separation, and divorce in Norway between 1975 and 
2015. Source: Statistics Norway [91].  
5.10 Educational and socioeconomic factors 
Wide socioeconomic inequalities in health are known to exist in the industrialised world. 
In health surveys, individuals are grouped by socioeconomic status based on educational level, 
income, or occupation. The relationship between socioeconomic status and health may have 
several explanations: health status may influence an individual’s ability to reach their 
educational goals, and that educational level may in turn influence their exposure to certain 
lifestyle variations and physical workplace and living conditions [92]. Inhabitants of Norway 
have the right to 12-13 years of free education, of which the first 10 years are mandatory. Thus, 
the educational system in Norway could be considered an important structural preventive 
measure that may decrease the burden of MSCs in the Norwegian population. It is likely that 
MSCs are associated with socioeconomic status. Reported associations have been consistent 
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regardless of the proxy of socioeconomic status used (educational level, household income, 
occupation) [35, 93, 94], indicating that educational level could be a reasonable variable to use 
when investigating the relationship between socioeconomic status and MSCs.  
5.11 Self-reported health information  
Participants of population-based surveys give good estimates of their own health. This has 
been shown for general health variables [95], questionnaires on mental health [96], and 
specific diseases [97, 98]. The strong association between self-reported health status and 
MSCs has been investigated in cross-sectional studies [15, 38, 46]. Blyth and colleagues 
reported a marked gradient in self-rated health across three pain groups, where respondents 
with poor self-rated health reported significantly more chronic pain compared to those who 
rated their health more positively (odds ratio [OR]: 7.24, 95% confidence interval [CI]: 5.87-
8.92) [38]. It is likely that quality of daily life is affected in those with longstanding MSCs. 
This was emphasised by Tschudi-Madsen and colleagues, who found a strong association 
between non-musculoskeletal symptoms and musculoskeletal pain symptoms [99]. Hagen and 
colleagues also found that self-rated symptoms of anxiety and depression was associated with 
MSCs without a specified body region [15]. A systematic review concluded that 
psychological factors played a significant role in the transition to chronicity in low back pain 
[100]. As MSCs are often multiregional, it is important to assess whether self-rated general 
health and mental health correlate with MSCs regardless of body region. Furthermore, if these 
measures predict subsequent MSCs, the associations should be brought to the attention of 
policymakers and clinicians in order to prevent MSCs and identify individuals at risk.  
5.12 Consequences of musculoskeletal complaints 
Reduced working capability due to MSCs explains a large portion of short- and long-term 
medically-certified sickness absence from work. These absences produces large costs not only 
for the social welfare system in Norway [101], but also for the employers, as they usually are 
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financially responsible for the first 16 days of sickness absence. Furthermore, sickness absence 
could be unfavourable for the patient [102]. All this reflects the important effects that MSCs 
have on the daily life of affected individuals. Thus, GP’s have a heavy responsibility when 
assessing the need for sickness absence, especially since objective measures of MSCs are 
sparse. There is no straight line between the presence of MSCs and the above-mentioned “soft 
end-point” (i.e. medically-certified sickness absence), as the GP determines when sickness 
absence is warranted. Actually, one could argue that medically-certified sickness absence is a 
poor outcome measure of MSCs, as it is the GP that produces it. Thus, when speaking of the 
long-term consequences of MSCs, it would be more interesting to study hard end-points such 
as mortality rates. Some studies have indicated an increased mortality among individuals with 
MSCs [103-106], but other studies did not support this [107-111]. In a systematic review from 
2014, Smith and colleagues concluded that the small number of studies and the heterogeneity 
between them made it difficult to provide a clear picture of the association between MSCs and 
mortality, and that further research should focus on how health, lifestyle, and social and 
psychological factors could influence this relationship in large population-based studies using 
a comparable methodology [112]. During the work on this thesis, there has been a growing 
body of evidence indicating that MSCs do not increase the risk of mortality independently [22]. 
However, there is still too much heterogeneity between these studies to make a definitive 
conclusion. Given the high prevalence of MSCs, it is crucial to examine if their presence 
influence mortality risk, and whether degree of severity influences this relationship.  
5.13 Objectives of this thesis 
The overall aim of this thesis was to explore the prevalence, risk factors, and consequences of 
MSCs in the general population of Northern Norway. The thesis consists of one cross-sectional 
study (Paper I), which examined the prevalence and severity of MSCs, and two prospective 
cohort studies (Papers II and III). Paper II was designed to assess predictors of MSCs 13 years 
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later in a cohort reporting absence of MSCs at baseline. Paper III was designed to assess 
subsequent mortality among those reporting MSCs at baseline during 21 years of follow-up. 
The prospective design of Papers II and III made it possible to assess predictors before the end-
points were measured (i.e. assess temporality).  
5.13.1 Specific research questions 
 
Paper I: 
1. What is the age-adjusted prevalence of MSCs in the municipality of Tromsø? 
2. How does age-stratification change the prevalence of MSCs?  
3. Is the prevalence of MSCs dependent of their severity and are there gender differences 
in the severity of MSCs? 
4. What are the possible sociodemographic, lifestyle, and self-reported health factors 
associated with the presence of MSCs? 
Paper II:  
1. Can specific health factors predict the presence of MSCs 13 years later in women and 
men reporting absence of MSCs at baseline? 
Paper III: 
1. Do women and men reporting MSCs at baseline have higher mortality rates from cancer, 





Tromsø is the largest city in Northern Norway. It is situated ≈400km north of the Arctic 
Circle, and has approximately 70,000 inhabitants. The population of Tromsø is relatively well 
educated, and a university and university hospital are located in the city. The physical living 
conditions are dominated by dramatic changes in daylight, with 2 months of midnight sun and 
2 months of polar night. A large part of the population of Tromsø has participated in a 
longitudinal, population-based, multipurposed health study called the Tromsø Study. The first 
health survey of the Tromsø Study (originally named the Tromsø Heart Study) took place in 
1974. When it was initiated, the goal of the Tromsø Study was to combat the high mortality 
rates from cardiovascular disease among Northern Norwegian men. In the 40 years since it 
began, over 45,000 inhabitants of the municipality of Tromsø have participated in one or 
more surveys of the Tromsø Study, and increasing emphasis has been placed on conditions 
other than cardiovascular disease [31]. The study currently consists of seven surveys (Tromsø 
1-7); The Tromsø 1 survey was conducted in 1974 and the Tromsø 7 survey in 2016 [113]. 
Information on MSCs was included in the questionnaires for the first time in the Tromsø 2 
survey (1979-80). The variables have been somewhat changed and updated between the 
Tromsø 2 and the Tromsø 7 surveys, and the participation rate for the seven surveys ranged 
from 62.4-77% [114]. Tromsø 4-7 surveys was conducted in two phases, with the most basic 
examination at the first visit, and more extensive examinations at the second visit. The 
participants received questionnaires several times throughout the study (appendices I-IV).  
6.1 Ethics  
The general approvals for the Tromsø Study were given by the Regional Committee of 
Research Ethics and the Norwegian Data Inspectorate and covered the objectives of this 
thesis. The Tromsø Study’s technical staff produced the datasets used in the analyses of the 
present thesis, including linkage of information collected from external sources (National 
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Register of Norway and Cause of Death Register). The 11-digit personal identification 
number was used to identify each participant in the linkage processes. The datasets were 
made anonymous before they were given to the authors. Written informed consent was 
obtained from all participants. In total, 181 participants attending the Tromsø 4 survey and 
two participants attending the Tromsø 6 survey withdrew their consent to participate in the 
research. The technical staff excluded these participants before the authors received the 
datasets.  
6.2 Study population 
The study population that constituted the basis for this thesis were participants who attended 
the Tromsø 4 and Tromsø 6 surveys, carried out in 1994/95 and 2007/08, respectively. These 
participants received two sets of questionnaires: the first (Q1) was distributed with the 
invitation letter and the second (Q2) was handed out when the participants attended the first 
phase of the respective survey. Tromsø 4 and Tromsø 6 surveys were included in this thesis 
because these surveys posed similar questions on MSCs. Total attendance rates for the seven 
surveys of the Tromsø Study are presented in Table 1. In the Tromsø 4 survey, all persons 
older than 25 years were invited (37,559 persons), 2,139 persons moved or died prior to the 
attendance date, giving an eligible population of 35,420 persons, of whom 27,158 (77%) 
attended. In the Tromsø 6 survey, it was not possible to invite total birth cohorts due to 
economic constraints, so a carefully considered selection of the population was invited: 
attendees at the second phase of the Tromsø 4 survey, a 10% random sample of individuals 
aged 30-39 years, all residents aged 40-42 and 60-87 years, and finally a 40% random sample 
of individuals aged 43-59 years, making the total number invited 19,762, of whom 12,984 
attended (65.7%) [31].  
In Paper I, 8,439 of the 12,984 participants of the Tromsø 6 study were eligible for inclusion, 
which provided a real participation rate of 42.7%. Paper II used baseline data from the Tromsø 
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4 survey and follow-up data from the Tromsø 6 survey. There were 10,326 participants that 
attended both surveys, of whom 4,496 were eligible for inclusion. Paper III used baseline data 
from the Tromsø 4 survey and follow-up data from the National Register of Norway and the 
Cause of Death Register. There were 26,977 participants who were eligible for inclusion (181 
participants withdrew their consent).  
Table 1. Participation in the seven health surveys of the Tromsø Study.  
Survey Year Invited Attended, n (%) 
Tromsø 1 1974 In total, 8,866 persons. 6595 (83 %) 
Tromsø 2 1979/80 In total, 21,329 persons. 16621 (74 %) 
Tromsø 3 1986/87 In total, 28,847 persons. 21826 (75 %) 
Tromsø 4 1994/95 In total, 37,558 persons. 27158 (women: 74 
%, men: 79 %) 
Tromsø 5 2001/02 In total, 10,353 persons 8130 (women: 81 %, 
men: 76 %) 
Tromsø 6 2007/08 In total, 19,762 persons 12984 (women: 68.4 
%, men: 62.9 %) 
Tromsø 7 2015/16 In total, 33,423 persons. 20870 men and 







6.3 Musculoskeletal complaints variables 
 
In the present thesis, MSCs were defined as having pain and/or stiffness in muscles and joints 
for at least 3 consecutive months during the previous year. Q1 of the Tromsø 4 survey (Papers 
II and III) included a screening question (“Have you during the last year suffered from pain 
and/or stiffness in muscles and joints that have lasted continuously for at least 3 months?”) 
with a binary response (yes/no) (appendix I). Those who answered yes to this question were 
posed additional questions regarding the duration and localisation of pain at the first medical 
examination. Using the American College of Rheumatology’s definition, participants were 
categorised as having or not having widespread MSCs (Paper III) [21]. In Q2 of the Tromsø 6 
survey (Papers I and II), the screening question (“Have you during the last year suffered from 
pain and/or stiffness in muscles and joints that have lasted continuously for at least 3 
months?”) was asked for each of six different body regions (neck/shoulder, arm/hand, upper 
back, lumbar back, hip/leg/feet, and other regions). Participants were asked to choose one of 
three responses (no complaints, mild complaints, or severe complaints) for each body region 
(appendix IV). As the Tromsø 6 survey did not include a single MSCs variable, the 
information from these six regions was merged into one variable to analyse the prevalence 
and severity of region-independent MSCs and associated factors (Paper I), and to analyse 
predictors of subsequent MSCs (Paper II). This was done in the following way: those 
answering “no complaints” on all six body regions were categorised as “no MSCs”, and those 
who answered “mild complaints” or “severe complaints” on at least one body region were 
categorised as “mild MSCs” and “severe MSCs”, respectively (Fig. 3). Additionally, 






Figure 3. The construction of one variable to analyse the prevalence and severity of region-
independent MSCs based on the questionnaire of Tromsø 6 (second questionnaire; Q2). 
Participants answering “no complaints [ikke plaget]” on all six body regions were categorised 
as “no MSCs”, and those who answered “mild complaints [en del plaget]” or “severe 
complaints [sterkt plaget]” on at least one body region were categorised as “mild MSCs” and 
“severe MSCs”, respectively.  
6.4 Sociodemographic, lifestyle, and self-reported health 
variables 
The Tromsø Study provided a wide range of information that could be used to analyse 
associated factors (Paper I), predictors (Paper II), and possible confounders (Paper III), 
depending on the aim of the analyses: smoking, self-reported health (i.e. general health status, 
mental health status, and chronic diseases), educational level, and leisure time physical 
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activity level. Additionally, BMI was calculated using the body weight/height data collected 
at the first medical visit. Age, gender, and marital status were collected from the National 
Register of Norway by the Tromsø Study’s technical staff. 
Paper I: Paper I investigated factors associated with MSCs, using variables collected from 
Q1 of the Tromsø 6 survey (appendix III). Participants were categorised according to their 
self-reported health status as either good or poor using a five-level ordinal general health 
variable (very good, good, neither good nor poor, poor, and very poor). The education 
variable had five levels: primary/secondary, technical, college, university <4 years, and 
university >4 years. Leisure time physical activity level was assessed through a validated 
questionnaire with four levels. Smoking status was categorised as current, former, or never 
smoker. Based on their BMI, participants were divided into 4 groups: <18.5, 18.5-24.9, 25-
29.9, and >30 kg/m2. Marital status was divided into married (including both registered 
partnership or married) and unmarried.  
Paper II: Paper II investigated the risk factors for MSCs using the variables collected in Q1 
of the Tromsø 4 survey (appendix I). Self-reported health status was categorised as either 
good or poor through a four-level ordinal general health variable (very good, good, poor, very 
poor). Smoking status was categorised as current smokers (current cigarette, cigar, or pipe 
smoker) and not current smokers. Mental distress was measured using the previously 
validated Cohort of Norway-Mental Health Index (CONOR-MHI), which is a seven-item 
questionnaire. Each item has a four-level scale ranging from “no” (1) to “very” (4). An 
average score was calculated from the seven items and the cut-off was set to 2.15, thus 
creating two groups: CONOR-MHI <2.15 and CONOR-MHI ≥2.15 (i.e. indicating mental 
distress) [96]. Leisure time physical activity level was determined from two questions (hard 
and light activity) and combined into a four-level physical activity index: sedentary (0 
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hours/week), low (<3 hours/week), moderate (3-5 hours/week), and high (>6 hours/week) 
[115]. BMI was divided into three groups: ≤24.9, 25.0-29.9, and ≥30 kg/m2. As in Paper I, 
marital status was divided into married (including both registered partnership or married) and 
unmarried.  
Paper III: The variables that served as potential confounders in the survival analysis were 
age, current smoking, mental distress (CONOR-MHI), educational level, and leisure time 
physical activity level. Additionally, self-reported chronic diseases (cardiovascular disease, 
cancer, diabetes, and asthma) were included. Participants were categorised as having a 
chronic disease if they reported one or more of the diseases listed. These variables were 
collected from both Q1 and Q2 of the Tromsø 4 survey. The analyses were also adjusted for 
BMI based on the measure of height/weight at the first medical visit. 
6.5 Mortality data 
In Paper III, information on all-cause and cause-specific mortality was made available 
through linkage between the Tromsø Study database and the National Register of Norway and 
the Cause of Death Register, respectively. The linkage process was ensured using the 11-digit 
personal identification number of each participant. All-cause mortality was based on the 
registration of a date of death in the National Register of Norway. Cause of death was 
classified according to International Classification of Diseases, 9th Revision (ICD-9) until 31 
December 1995 and according to the International Classification of Diseases, 10th Revision 
(ICD-10) thereafter. Causes of death were categorised as cardiovascular disease death (ICD-9 
codes: 390–459; ICD-10 codes: I00-99) or cancer death (ICD-9 codes: 140–239, and ICD-10 
codes: C00-97). Information on all-cause mortality was updated until 17 October 2015 and 
cause-specific mortality was updated until 31 December 2012.  
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6.6 Variables with missing information 
During the process of writing the present thesis, there were challenges with missing values on 
questionnaire variables that demanded attention.  
Paper I. In Q2 of the Tromsø 6 survey, large number of participants provided an incomplete 
set of MSCs variables (i.e. one or more of the six variables were left unanswered). After 
excluding participants >80 years of age, there were 4,012 participants with incomplete MSCs 
data that were excluded, giving a total number of participants of 8,439. Among the population 
included in the first paper (N=8,439), missing values on independent variables were: BMI 
(n=7), self-reported health status (n=47), smoking status (n=81), educational level (n=72), 
leisure time physical activity level (n=465) and marital status (n=0)  
Paper II. Of the 26,977 participants that returned Q1 of the Tromsø 4 survey (and consented 
to research), 29 lacked an answer to the screening question on MSCs and had to be excluded. 
There were 10,326 participants who attended both the Tromsø 4 and Tromsø 6 surveys, of 
whom 6,415 reported no MSCs at baseline (Q1 of the Tromsø 4 survey) constituting the 
eligible population of Paper II. At follow-up (Q2 of the Tromsø 6 survey), 1,785 participants 
had incomplete MSCs data as explained for Paper I. In Paper II (N=4,496), missing values on 
independent variables were: BMI (n=5), self-reported health (n=2), smoking status (n=7), 
educational level (n=8), leisure time physical activity level (n=40), marital status (n=6) and 
mental health complaints (n=67). 
Paper III. The corresponding figures for the participants with missing data at baseline (Q1 
and Q2 of the Tromsø 4 survey) (N=26,977) were: BMI (n=57), smoking status (n=24), 
educational level (n=103), leisure time physical activity level (n=283), mental health 
complaints (n=788) and self-reported chronic diseases (n=3270). The high number of missing 
information on self-reported chronic diseases was explained by information on cancer disease, 
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which was collected in Q2 (N=24,724), in contrast to the other diseases (asthma, diabetes, 




7 Statistical methods 
7.1 Descriptive statistics 
Descriptive statistics of the categorical variables (Papers I-III) were compared with cross-
tabulation, and the chi-square test was applied. The chi-square test estimates the probability of 
finding the observed difference in the sample (or more extreme) under the assumption that the 
null hypothesis is true. This test should not be applied if there are cells in the cross-table with 
values less than 5. This assumption was met. Our large-scale studies provided very large 
sample sizes, which can lead to an increase in the calculated chi-square value independent of 
the strength of the relationship between the variables (p. 109 [116]). Therefore, the 
relationships were further investigated using regression and survival models. 
One-way analysis of variance (ANOVA) was performed to examine the descriptive statistics 
of continuous independent variables on the nominal three-level dependent MSCs variable 
(Papers I and II), and a post-hoc test was applied when appropriate (chapter 9 [117]). 
ANOVA is suitable to examine differences in means between the three MSCs categories if 
samples are randomly chosen from the population, the independent variable is normally 
distributed, and the variance is similar in the different groups within the sample. The post-hoc 
test chosen was the Tukey test, which is a conservative test when the groups are of unequal 
size, as they were in our studies (Papers I and II). In Paper III, descriptive statistics of 
continuous variables associated with the dichotomised MSCs variables were analysed using 
the independent samples t-test. Both the assumption of normal distribution and equality of 
variance were met (pp. 140-141 [117]) 
7.2 Logistic regression analysis 
In order to estimate associations between the binary outcome of MSCs (mild and/or severe 
versus no MSCs) and sociodemographic, lifestyle, and self-reported health information (Paper 
I), and to estimate if these factors predicted subsequent MSCs (Paper II), logistic regression 
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analyses were the natural choice [116, 118]. All analyses were performed unadjusted, age-
adjusted, age- and gender-adjusted, and finally, multivariable logistic regression analyses 
were performed. Interaction term analyses were performed to assess if significant gender 
differences could be revealed. In Paper II, regression analyses were also performed for severe 
MSCs (versus mild or no MSCs) and multiregional MSCs (≥3 regions versus <3 regions), and 
the multivariable regression models were graphically presented. The associations were 
presented as ORs with 95% CIs for women and men, separately. All participants with missing 
values for any of the independent variables were excluded.  
7.3 Survival analysis 
The analyses of mortality rates for participants with MSCs versus no MSCs, and widespread 
MSCs versus no widespread MSCs, were undertaken with the Cox proportional hazard model 
(Paper III) [118]. Time from attendance date at baseline (Tromsø 4) to death, emigration, or 
the end of the study was entered as survival time. Results were presented as hazard ratios 
(HR) with 95% CIs for women and men, separately. A HR >1.0 indicated that the MSCs 
group or widespread MSCs group, had an increased mortality risk compared to those without 
such complaints at baseline. The analyses were performed unadjusted, age-adjusted, and 
finally multivariable Cox regression models were performed. Additionally, the unadjusted 
Cox regression model was stratified on 10-year age groups and presented graphically. All 
participants with missing values for any of the independent variables were excluded. The 
assumption of proportionality of mortality risk over time was checked by comparing the 
survival curves of the unadjusted Cox regression models. Crossing curves were not found in 
the analysis of MSCs or widespread MSCs, indicating a satisfied assumption of 




7.4 Level of statistical significance 
For all the above-mentioned analyses, a p-value <0.05 was considered statistically significant. 
7.5 Statistical software 




8 Main results 
8.1 Paper I: Prevalence and severity of musculoskeletal 
complaints  
Overall, the age-adjusted prevalence of MSCs in one or more body regions was 15.8% (95% 
CI: 15.0-16.6) and 42.4% (95% CI: 41.4-43.5) for severe and mild MSCs, respectively. Most 
of the participants with MSCs (72.3%) had more than two body regions involved. The highest 
prevalence of MSCs in the specified body regions was found in the neck and shoulders (severe 
complaints: 8.9% [95% CI: 8.3-9.5]; mild complaints: 34.2% [95% CI: 33.1-35.2]). Among 
those reporting MSCs from more than five body regions, women had nearly three times higher 
prevalence than men (14.9% versus 5.6%). Age-stratified analyses revealed that the prevalence 
of mild MSCs increased steadily with age. Severe MSCs had the highest prevalence in the age 
group 50-59 years. Multivariable regression analyses showed that respondents with MSCs were 
more likely to have coexisting negative health factors, and some gender differences in the 
distribution of such factors were observed.  
8.2 Paper II: Predictors of future musculoskeletal complaints  
The overall multivariable logistic regression analyses revealed that female gender predicted the 
presence of MSCs 13 years later (OR: 1.46, 95% CI: 1.29-1.66). The strongest predictor in this 
analysis was low educational level at baseline (primary/secondary or technical school) with an 
OR of 1.73 (95% CI: 1.46-2.05), followed by poor self-reported health status (OR: 1.62, 95% 
CI: 1.30-2.02). BMI ≥30 kg/m2 (OR: 1.39, 95% CI: 1.10-1.77) and current smoking (OR: 1.33, 
95% CI: 1.16-1.52) also increased the risk of future MSCs, in contrast to age and physical 
inactivity, which were not significantly associated in any direction. The gender stratification of 
the analysis revealed that mental health complaints (i.e. depression and/or anxiety) predicted 
MSCs in men (OR: 2.03, 95% CI: 1.18-3.50). Current smoking, low educational level, and poor 
self-reported health status were slightly stronger predictors of MSCs among women than men, 
but they were not statistically significant.  
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8.3 Paper III: Musculoskeletal complaints and mortality risk 
The crude Cox regression analyses revealed an increased risk of all-cause mortality among 
females (HR: 1.36, 95% CI: 1.26-1.46) and males (HR: 1.35, 95% CI: 1.25-1.45) who reported 
MSCs. The same applied for participants with widespread MSCs. In the multivariable Cox 
regression analyses (adjusted for age, smoking, mental health complaints, educational level, 
BMI, leisure time physical activity level, and self-reported chronic diseases), MSCs did not 
predict all-cause mortality among women (HR: 0.93, 95% CI: 0.85-1.01) or men (HR: 0.93, 
95% CI: 0.85-1.01). Widespread MSCs were not found to significantly predict the risk of all-
cause mortality in either women (HR: 0.90, 95% CI: 0.80-1.01) or men (HR: 0.87, 95% CI: 
0.76-1.00). The cause-specific mortality analyses did not add any information to these findings. 
Another interesting finding revealed in the preliminary analyses of Paper III was that, when 
self-reported health status was included as a covariate in the multivariable Cox regression 
analysis, the MSCs and widespread MSCs groups had a HR <1.0, indicating a significantly 
lower mortality than that observed among those without MSCs or widespread MSCs. The 
variable self-reported health was excluded from the final analyses due to a significant 





9.1 Methodological considerations  
This large-scale, population-based study examined several aspects of a population reporting 
pain and/or stiffness in muscles and joints lasting for 3 months or more during the past year 
(MSCs). Adult women and men from a general population of Northern Norway were 
included. Overall, the Tromsø Study surveys have high response rates, but the response rate 
was heavily reduced by incomplete MSCs data in Tromsø 6 (paper I and II).  
Even though there were differences in how participants were asked to report the presence and 
severity of MSCs between the two Tromsø surveys in this thesis, the same definition of MSCs 
was used in all of the papers: one cross-sectional and the two prospective cohort studies. 
Moreover, in the prospective studies (Papers II and III), the baseline variables were reported 
without knowledge of the future outcome (MSCs or mortality, respectively). Finally, the 
population-based approach reduces the chances that data are influenced by health-seeking 
behaviour or diagnostic processes. However, in this epidemiological study there are several 
methodological considerations to discuss in order to assess the generalisability of our results 
to other populations. 
9.1.1 Systematic errors 
Information sampled in the Tromsø 4 survey (1994/95) came from total birth cohorts older 
than 25 years of age, and the response rate was very high (77%). Moreover, the Q1 and Q2 of 
the Tromsø 4 survey did not have a large number of non-responders, and 91% of the attendees 
of Tromsø 4 also finished Q2 (N=24,724). Baseline data for Papers II and III were collected 
from the Tromsø 4 survey cohort, which is a middle-class Caucasian population likely to be 
representative of the Tromsø population [31]. Information from the Tromsø 6 survey 
(2007/08) constituted the basis for Paper I, and also provided follow-up data for Paper II. Due 
to economical constraints, it was necessary to carefully consider invitees in order to produce a 
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representative sample of the population (see 6.2 Study population). Of the 19,762 individuals 
invited to the Tromsø 6 survey, 12,984 responded to Q1 and attended the first visit, providing 
a response rate of 65.7%, which is considered high in population-based health surveys that 
include medical examinations [119]. The Tromsø 6 survey cohort is considered representative 
of the adult population of Tromsø [31]. In sum, the population-based approach chosen in this 
thesis should not have produced selection bias (p. 134, [120]). 
As most participants answered Q2 at the site of the first medical visit, a total of 12,440 
participants answered both Q1 and Q2, but only 8,439 participants (42.7 % of the invited) 
completed a full MSCs questionnaire in Q2. The questions on MSCs in Q2 of the Tromsø 6 
survey constituted the outcome variables in Papers I and II, and missing values constituted a 
challenge. Unlike the Tromsø 4 survey, this questionnaire lacked an overall MSCs variable to 
enable the assessment of region-independent prevalence of MSCs. Thus, we created an 
overall MSCs variable by combining responses from all body regions as described in the 
Statistical Methods section. Nevertheless, Q2 provided the opportunity to give a negative or 
positive response at individual body regions. Early in the analytical process, it became 
obvious that a large portion of participants with MSCs at one body region tended to skip 
responding to the rest of the body regions. This was further complicated by the fact that a 
somewhat smaller group of participants gave negative responses to some, but not all, body 
regions. In addition, some participants did not report data on any of the body regions.  
A complete-case approach was chosen, providing 8,439 participants with self-reported MSCs 
data from the Tromsø 6 survey. A sensitivity analysis was performed by coding the missing 
answers as “no complaints”, which led to a slightly increased prevalence of MSCs in the 
Tromsø 6 survey, indicating that the complete-case approach produced conservative 
prevalence estimates. There were statistically significant differences between the population 
with complete data and those with incomplete data regarding the descriptive statistics (Papers 
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I and II). As part of the sensitivity analysis, the logistic regression analysis remained 
unchanged compared to the complete-case approach. Based on this, a complete-case approach 
was also chosen for the follow-up data in Paper II. The handling of incomplete data on MSCs 
in this thesis may have violated the representativeness of the sample, as it likely led to 
including participants who fully understood the questionnaires. If so, the results could 
underestimate what could be expected in another population. This would have fewer 
implications on the interpretation of the logistic regression analyses performed in Papers I and 
II. Even though the effect size diminished, the significant associations revealed in the 
sensitivity analyses remained significant in the multivariable models when a complete-case 
approach was chosen. In sum, with the overall high response rates of the Tromsø Study and 
our above-mentioned sensitivity analyses of missing data handling, the results of this thesis 
should be valid for the source population of Tromsø.  
9.1.2 Random error  
The risk of our findings not being reproducible due to random error or imprecision was 
reduced by the large sample size in the study. Furthermore, random error was addressed by 
appropriate statistical methods, by which a p-value of 5% was used to test the hypotheses and 
95% CIs were computed. When the p-value exceeded 5% (non-significant finding) and/or the 
CI included 1 (OR in Papers I and II, HR in Paper III), the null hypotheses were retained and 
the finding was reported accordingly (pp. 148-161 [120]). The risk of type I error (i.e. 
rejecting a null hypothesis that is true) was inflated due to multiple testing. To avoid that, a 
Bonferroni correction was used (Paper II) to calculate a lower p-value, providing a more 
conservative basis for discarding the null hypotheses (p. 236 [120]). Reducing the chance of 
type I error increases the risk of type II error (i.e. retaining a null hypothesis that is false). 
However, the large sample size, p-values clearly below 5%, and overall narrow CIs minimises 
the risk of type II as well as type I errors.  
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9.1.3 Information and classification bias 
The MSCs variables in the Tromsø 4 and Tromsø 6 surveys had a binary (yes/no) and a three-
level ordinal (no/mild/severe) response, respectively. In Paper I, the overall prevalence of any 
MSCs (mild or severe MSCs together) was higher than the prevalence reported in another 
study of a Norwegian general population using a binary response variable with the same 
definition of MSCs [15]. We hypothesise that some of the participants answering “no” to a 
binary response variable may have reported “mild complaints” if presented an ordinal 
response variable. Hence, we will not claim that MSCs are de facto more prevalent in the 
Tromsø population compared to other populations, and therefore the higher prevalence of 
MSCs presented in this thesis is not regarded as an indication of poor generalisability of the 
results. This is further emphasised by the fact that the prevalence of MSCs in the Paper III 
(binary response variable) was 35.7%, which is comparable to other studies [14, 35, 38, 46, 
121]. During the work on this thesis, it was interesting to discover that the Tromsø Study 
included variables on symptoms from the musculoskeletal system that differed slightly from 
survey to survey, but also within one survey. In the Tromsø 6 survey, Q1 had a binary 
response pain question with a slightly different definition of pain than that used for MSCs 
included in this thesis. Participants were asked if they had “persistent or constantly recurring 
pain lasting for 3 months or more”, and about 35% of the participants answered yes [122]. 
When designing the methods of Paper II, we claimed that this phrasing was not comparable to 
our 1-year prevalence variable of MSCs at baseline (Tromsø 4). However, it could be 
questioned how much the phrasing of these two different variables influences the prevalence. 
In Q2 of the Tromsø 6 study, immediately after the six MSCs body regions, the participants 
were presented with another set of questions with the exact same layout, but asking for MSCs 
during “the latest 4 weeks” instead of “at least 3 months in the last year” (i.e. 1-month and 1-
year prevalence, respectively). An explorative and preliminary analysis of the agreement 
between these variables revealed a very high degree of agreement on all body regions. Of 
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course, this should be interpreted with caution, as it is not contradictory to have MSCs 
prevalent in the last month and the last year at the same time. However, it might imply that 
different phrasing of MSCs variables has fewer implications on a survey’s case-finding 
ability. The most recent survey, Tromsø 7, adopted MSCs variables from the Tromsø 6 
survey. Thus, future analyses of the Tromsø Study can be performed with consistent data. 
Besides the questionnaires of health surveys included in CONOR [123], there is no national 
standard of MSCs questionnaires in Norwegian health surveys. Such an initiative would 
improve the Norwegian epidemiological research on musculoskeletal health. 
Well-established questionnaires provided information on the covariates examined in this 
thesis, and data were collected at study enrolment, minimising the chance of recall bias. 
Additionally, height and weight were measured in a standardised way and were used to 
calculate BMI. Although the transformation of a continuous variable of BMI to a categorical 
one in order to simplify the analysis may hide important nuances, with ordinal variables of 
four to five categories the loss of information is quite small [124]. The analyses including 
BMI as a continuous variable did not reveal contradictory findings (Paper I). Furthermore, as 
covariates were collected at study enrolment, it was difficult to adjust for changes during 
follow-up in Papers II and III. For instance, current smokers at enrolment could have stopped 
smoking, and non-smokers could have started. However, as the included participants were 
older than 25 years in Papers II and III, and the average age for starting smoking in Norway is 
18 years for women and men [125], we can assume that the group of non-smokers in these 
samples is quite stable. Thus, regarding smoking status, most of those who change their 
smoking status are stopping smoking, reducing their exposure time to tobacco. This may lead 
to an underestimation of tobacco smoking as a risk factor for MSCs.  
Mortality data from the Cause of Death Registry is problematic, as the physician writing the 
death certificate is the one to register cause of death. Diagnoses on death certificates have low 
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reproducibility, and autopsy can result in a changed cause of death [126-128]. In the present 
thesis, potential inconsistencies in the registered cause of death were compensated by the 
highly valid all-cause mortality data that relied on a date of death collected from the National 
Register of Norway. 
9.1.4 External validity 
Can the results of this study be generalised to other populations? External validity is 
dependent on internal validity. With the above-mentioned methodological considerations, the 
internal validity of this thesis is mostly dependent on what the MSCs variables are actually 
measuring in the study sample. We must assume that those categorised as having MSCs in 
this thesis truly have had such complaints (more or less severe) the last year before the time of 
survey, and likely also with duration of three months according to the phrasing of the 
variables. Furthermore, as MSCs are subjective by definition, and not a defined 
pathophysiological “event” that occurs or not, it should not be very controversial to claim that 
the degree of MSCs and the presence of MSCs can fluctuate with time [121]. Hence, the 
study design provided no data on the burden of MSCs in between the two points of 
measurement in Paper II, or between baseline and the defined end-points in Paper III. Thus, 
the generalisation of the associations between predictors of MSCs and the association 
between MSCs and mortality should be done with some caution regarding the possible 
fluctuation of MSCs with time. However, Landmark and colleagues [129] concluded that the 
use of simple recall questions shows considerable stability of pain. One should be less 
concerned about fluctuations of pain over time when measuring chronic pain by recall in 
population studies, and in their study this was further emphasised by the fact that current pain 
was highly correlated with previous pain, indicating that the methods were able to sample a 
population that is bothered by pain over time [129]. Generalisation should always be done 
with caution. The Tromsø study population is considered representative of an urban middle-
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class adult Northern European Caucasian population [31, 114], and therefore the 
generalisability of the present thesis should be limited accordingly. 
9.2 Discussion of the results 
The results of each paper are discussed in detail therein. This section will elaborate on the 
results and possible implications.  
The prevalence of MSCs in Paper I was higher in women than in men; in particular among 
those reporting MSCs from ≥5 body regions. The results of Tschudi-Madsen and colleagues 
support these figures [99], as do those of Parot-Schinkel and colleagues [130]. More than half 
of the participants reported any MSCs lasting for at least 3 months the previous year. The 
handling of missing data produced slightly conservative prevalence estimates, indicating that 
it is more common to have any one MSC than none at all. GPs should be aware of this when 
seeing patients with musculoskeletal symptoms and include it in the conversation to 
reassuring the patient. One-fifth of consultations in primary care are due to symptoms or 
diseases of the musculoskeletal system [6, 8]. Compared to the high prevalence in the general 
population, the lower prevalence of MSCs reported in primary care suggests that the 
population provides a large-scale selection of which symptoms lead to health care use. 
However, each individual handles their illness in a unique manner, and the ability to interpret 
symptoms varies with the individual’s previous experiences, acquired knowledge, and 
presence of a support network [131]. Green and colleagues stated that disease has become the 
focus of the technological and market-driven medical systems, while illness and the socio-
cultural aspects of medicine have blurred into the background. Fostering attitudes, values, and 
communication will improve understanding of the meaning and context of a patient’s illness 
[10]. The GP’s focus on patient’s ideas, concerns, and expectations in addition to an adequate 
examination of the musculoskeletal symptoms might effectively help to differentiate between 
musculoskeletal symptoms within the normal range, which could benefit from a reassuring 
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approach, and individuals presenting symptoms and clinical signs that should undergo further 
medical investigations. 
Another important finding of Paper I was that, among those reporting any MSCs, nearly 
three-quarters had complaints from more than one body region. This finding may be more 
important than the prevalence of MSCs at specified body regions. The number of body 
regions affected was strongly associated with other symptoms, functional status, and a 
negative health profile in general [29, 99, 132]. Thus, if we view multiregional MSCs as an 
indicator of a poor health profile, better prevention of MSCs could be beneficial to public 
health. The results of Paper I underline this by revealing that those reporting MSCs were 
more likely to simultaneously report tobacco smoking, be obese, and have a poor self-
reported health status. These associations are supported by other large-scale studies [15, 56, 
68]. Hagen and colleagues reported a strong association between poor self-reported health 
and MSCs, similar to the corresponding figures in Paper I. The same applies for tobacco 
smoking. Hence, it is a major strength that the results are similar, despite some differences in 
the MSCs variable.  
Paper II filled the gaps of Paper I by adding temporality to the associations. The aim of Paper 
II was to examine if specific health factors predicted the presence of MSCs 13 years later in 
women and men reporting absence of MSCs at baseline. Also here, smoking status, self-
reported health status, and educational level were associated with MSCs. The ORs 
corresponding to these associations were slightly higher in women than in men, as found in 
Paper I, but the differences were not statistically significant. Current smokers were more 
likely to report MSCs (OR: 1.33, 95% CI: 1.16-1.52) at the time of follow-up in Paper II 
compared to non-smokers. The biological mechanism by which this occurs cannot be 
determined with the present study design. Nevertheless, through the ability to assess 
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temporality, this study adds a possible reduced burden of MSCs to the list of positive effects 
of less tobacco smoking.  
A dose-response relationship was found between leisure time physical activity level and 
MSCs among women in the age-adjusted logistic regression model in Paper II, but this was 
lost when adjusting for other covariates. In Paper I, this association was not that prominent, 
but a gender difference was present in both papers. Magnusson and colleagues found that the 
onset of widespread MSCs was likely a result of a combination of obesity, mental distress, 
poor physical fitness, and poor sleep quality, and that poor physical fitness was the most 
likely factor to interact with other covariates [57]. The analyses in Paper II were checked for 
interactions between the factors included. Hence, the loss of significant associations between 
MSCs and leisure time physical activity level in the multivariable analyses of the present 
thesis is less likely to be a result of over-adjustment. Landmark and colleagues suggested that 
the relationship between exercise and MSCs was close in time. That is, in times when 
participants exercised more, they reported less MSCs [84]. In Paper II, changes in leisure time 
physical activity level during the 13-year follow-up period might dilute the associations. If the 
lack of significant associations reported in Paper II can be explained by methodological 
issues, then physically inactive women might realistically be more vulnerable to MSCs than 
men. The strong association between MSCs and mental health distress was in agreement with 
Hagen and colleagues [15], but in Paper II the association was found only in men. Mental 
health distress also predicted MSCs in the lumbar back and lower extremities in Paper II. The 
present thesis adds to this research, showing that men facing mental distress may be more 
vulnerable to MSCs than women. 
In Paper II, the prevalence of MSCs was 54.6% at follow-up. When more than half of the 
population reports MSCs, one should suspect a heterogeneity in the aetiology of these 
complaints. This study was able to indicate characteristics of individuals at risk for 
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subsequent MSCs, but the assumed heterogeneity and the observational study design make it 
difficult to claim that the exact mechanisms behind developing MSCs could be assessed. 
Hence, causal inference with the associations found in Paper II should be interpreted with 
caution. On the other hand, the similar findings of Papers I and II strengthen the present 
thesis’ ability to describe health characteristics associated with MSCs. The gender difference 
in the prevalence of MSCs could not be explained by any risk factors that were more 
significantly associated with MSCs in women than men.  
When reviewing the associations presented in Paper II, it could be debated whether it is more 
appropriate to report incidence proportion (and risk ratios) rather than ORs in a prospective 
study design. McBeth and Jones discussed the different measures of reporting rates of 
musculoskeletal pain in their review from 2007. They suggested that musculoskeletal pain is 
episodic and has a poorly-defined onset. This makes it problematic to use the term incidence 
(or first ever), as the “incident cases” reported in some studies are probably prevalent 
episodes identified among individuals who were symptom-free at the time of enrolment in a 
study [121]. With the high prevalence at follow-up in Paper II, it is expected that the OR is 
higher than a risk ratio would be (p.166 [116]), and this might give the impression of a 
stronger relationship than that which was actually found. But taking the aim and design of the 
study and the above-mentioned considerations into account, the presentation of ORs is 
justified and does not violate the conclusions of Paper II.  
The present thesis did not evaluate the effect of different preventive strategies or treatment of 
MSCs. Thus, it cannot be claimed that aiming interventions towards smoking cessation will 
influence the course of the MSCs as an isolated health issue. However, focusing on the 
general risk profile of an individual level is an important task for GPs, and increasing the 
knowledge on factors that contribute to MSCs is crucial in developing strategies for 
prevention [9]. The present thesis demonstrated that there might be a potential to reduce 
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general risk factors among people reporting MSCs to decrease such health problems. 
Additionally, 85% of all Norwegian municipalities actually have a position dedicated to 
coordinating public health services, including preventive strategies [133]. Taking the above-
mentioned associations into account, these coordinators should be aware that MSCs can be 
used as an indicator of health status. 
In order to explore the health status of people reporting MSCs further, Paper III aimed to 
assess if they had higher mortality rates than people reporting no MSCs. Even though results 
from population-based studies can give valuable information to primary care providers, their 
scientific and clinical relevance increases when they are connected to other information 
sources such as the Cancer Registry of Norway, the Cause of Death Register, or the National 
Register of Norway. Connecting data from these sources provides almost infinite possibilities 
to explore factors that prevent and promote illness and disease. Due to the existence of the 
Norwegian personal identification number and the national mortality information from the 
National Register of Norway, it is possible to produce highly valid data. In a systematic 
review from 2014, Smith and colleagues concluded that there was a divergence in the 
evidence on the relationship between MSCs and mortality [112]. Through Paper III, the 
present thesis responds to the concerns raised by this systematic review. The analyses 
conducted and reported in Paper III gave no indication that MSCs or widespread MSCs 
present at baseline are independent risk factors for mortality. The increased mortality rates in 
crude analyses were lost when adjusting for possible confounders, and no gender differences 
in mortality rates were revealed. Thus, neither the gender difference in the prevalence of 
MSCs, nor the peak in the prevalence of severe MSCs at age 50-59 years found in Paper I, 
could be attributed to increased mortality risk among respondents with MSCs. Åsberg and 
colleagues published a study using a methodology that was very similar to that used in Paper 
III [111], and found no increased mortality among respondents with MSCs or widespread 
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MSCs. This was further determined through their systematic review [22]. Together with the 
updated literature on the field, the present thesis addressed the concerns of Smith and 
colleagues [112] about incongruent methodologies blurring the evidence of mortality risk 
among respondents with MSCs.  
Poor self-reported health has been related to higher mortality rates [95, 134], and it was also 
the strongest factor associated with MSCs in Paper I. Therefore, the preliminary analyses of 
Paper III were adjusted for poor self-reported health. Significantly, a lower risk of all-cause 
mortality among respondents with MSCs compared to those reporting no MSCs was found. 
Due to significant interaction analyses, the self-reported health variable was excluded from 
the final analyses. This preliminary analysis could indicate that when one’s general health 
perception is poor due to MSCs, the mortality risk is lower than when this perception is poor 
due to other, known deadly diseases. Based on this we infer that presence of MSCs is not an 
independent risk factor for subsequent death, despite the higher burden of other risk factors 
and poorer self-reported health among people reporting MSCs. In clinical settings, this 
finding is of importance. Patients can be reassured that, even though the MSCs they 
experience are influencing their daily life and well-being, their presence do not reduce life 
expectancy. Such information may have a symptom-relieving effect in itself.  
There are however limitations in the study design of Paper III that might hide a true 
association between MSCs and mortality, i.e. MSCs were only measured at baseline. Thus, it 
is possible that those who reported no MSCs at baseline experienced them during follow-up, 
but remained classified as no MSCs, which may have blurred the results. Further, the 
prevalence of MSCs at baseline was high, and it would be somewhat sensational if this large 
group had a higher mortality risk, even if the increased risk was small. However, if the lower 
prevalence of widespread MSCs indicates a higher clinical significance than MSCs overall, 
one should expect Paper III to be able to reveal an increased mortality risk in this group of the 
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population, if present. This was not the case in Paper III. So with the limitations of sampling 
participants with MSCs mentioned in the section 7.1.3 Information and classification bias, it 





10 Final conclusion 
• Based on data from the Tromsø Study, more than half of the population report any MSCs, 
indicating that it is more common to have at least one MSC than none.  
• Presence of MSCs was dependent on the reported severity of complaints; prevalence of 
mild MSCs steadily increased with age, while prevalence of severe MSCs peaked in the 
50-59-year age group. 
• The peak in MSCs prevalence is probably not associated with a higher mortality risk 
among those reporting MSCs.  
• Reporting MSCs was associated with a negative health profile, which indicates that 
people suffering from MSCs have the potential to improve their general health. 
• Mental health distress (i.e. symptoms of depression and/or anxiety) tended to predict 
MSCs in men more than women.  
• Leisure time physical activity level was not associated with MSCs in the cross-sectional 




11 Future research 
MSCs are a costly public health problem in Norway and in other Western countries due to 
their heavy burden on social welfare systems [51]. MSCs constitute a large group of patients 
in primary care. Diagnosing, treating, and evaluating patients with these health issues is 
mostly done by GPs. Combining this with the task of acting as a gatekeeper for the social 
welfare system is challenging. The present thesis shows that a considerable part of a general 
population reports MSCs and points out predictors of reporting MSCs later in life. A small 
reduction in the burden of MSCs would have large positive consequences. Future 
epidemiological research should aim to investigate the proportion of the population that 
reports absence of MSCs in several consecutive health surveys, as little is known about which 
characteristics maintain the absence of MSCs. Such an approach could provide a better 
homogeneity in the sample than the present thesis was able to. Many authors have explained 
differences in MSCs prevalence across studies by differences in the definition of MSCs [51, 
121]. The present thesis supports the notion that the layout and phrasing of MSCs 
questionnaires have an impact on prevalence of MSCs. However, a survey’s case-finding 
ability might not be dependent of different phrasings of questions. The Tromsø Study 
provides a unique opportunity to compare responses to different questionnaires regarding 
MSCs. The results of such an examination may support a simplification of already wide-





• Paper I, methods section: “all residents of Tromsø aged 42-44”. It should say 40-42 years.  
• Paper I, II and III, methods sections: Age, gender and marital status were collected from 
the National Register of Norway by the Tromsø study’s technical staff before the datasets 
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    Appendix  III
First questionnaire of Tromsø 4 (Q1)     





c Verken god eller dårlig
c Dårlig 
c Meget dårlig
2 Hvordan synes du at helsen din er sammenlignet 






3 Har du eller har du hatt? Ja Nei
Alder første 
gang
Hjerteinfarkt ............................................................... c c
Angina pectoris (hjertekrampe) ....................... c c
Hjerneslag/hjerneblødning ........................... c c
Hjerteflimmer (atrieflimmer) .............................. c c
Høyt blodtrykk ......................................................... c c
Beinskjørhet (osteoporose) .................................. c c
Astma ............................................................................... c c
Kronisk bronkitt/emfysem/KOLS ........... c c
Diabetes ......................................................................... c c
Psykiske plager (som du har søkt hjelp for) ....... c c
Lavt stoffskifte .......................................................... c c
Nyresykdom, unntatt urinveisinfeksjon... c c
Migrene .......................................................................... c c
4 Har du langvarige eller stadig tilbakevendende 
smerter som har vart i 3 måneder eller mer?
c Ja c Nei
5 Hvor ofte har du vært plaget av søvnløshet de siste 
12 måneder? 
c Aldri, eller noen få ganger
c 1-3 ganger i måneden
c Omtrent 1 gang i uken
c Mer enn 1 gang i uken
6 Under finner du en liste over ulike problemer.  
Har du opplevd noe av dette den siste uken  









Plutselig frykt uten grunn ....... c c c c
Føler deg redd eller  
engstelig ................................................ c c c c
Matthet eller svimmelhet ...... c c c c
Føler deg anspent eller 
oppjaget ................................................ c c c c
Lett for å klandre deg selv .... c c c c
Søvnproblemer ................................ c c c c
Nedtrykt, tungsindig .................. c c c c
Følelse av å være unyttig, 
lite verd .................................................. c c c c
Følelse av at alt er et slit ......... c c c c
Følelse av håpløshet  
mht. framtida ................................... c c c c
7 Har du i løpet av de siste 12 måneder vært hos:  
Hvis JA; Hvor mange ganger?
Ja Nei Ant ggr
Fastlege/allmennlege ......................................... c c
Psykiater/psykolog ............................................... c c
Legespesialist utenfor sykehus 
(utenom fastlege/allmennlege/psykiater) ........... c c
Fysioterapeut ............................................................. c c
Kiropraktor ................................................................... c c
Annen behandler
(homøopat, akupunktør, fotsoneterapeut, natur-
medisiner, håndspålegger, healer, synsk el.l) ..... c c
Tannlege/tannpleier ............................................ c c
Skjemaet skal leses optisk. Vennligst bruk blå eller sort 
penn. Du kan ikke bruke komma, bruk blokkbokstaver.
2007 – 2008 KONFIDENSIELT
9 Har du gjennomgått noen form for operasjon i løpet 
av de siste 3 årene?
c Ja c Nei
8 Har du i løpet av de siste 12 måneder vært på sykehus? 
Ja Nei Ant ggr
Innlagt på sykehus ................................................ c c
Konsultasjon ved sykehus uten innleggelse;
Ved psykiatrisk poliklinikk .................. c c
Ved annen sykehuspoliklinikk ........ c c
BRUK AV HELSETJENESTER
HELSE OG SYKDOMMER
19 Hva er din hovedaktivitet? (Sett ett kryss)
c Yrkesaktiv heltid c Hjemmeværende
c Yrkesaktiv deltid c Pensjonist/trygdet
c Arbeidsledig c Student/militærtjeneste
10 Bruker du, eller har du brukt, noen av følgende 






Medisin mot høyt blodtrykk ... c c c
Kolesterolsenkende medisin .... c c c
Medisin mot hjertesykdom .... c c c
Vanndrivende medisin ................ c c c
Medisin mot beinskjørhet 
(osteoporose) ............................................ c c c
Insulin ........................................................ c c c
Diabetesmedisin (tabletter) ........ c c c
Stoffskiftemedisinene  
Thyroxin/levaxin ............................. c c c
11 Hvor ofte har du i løpet av de siste 4 ukene brukt 











på resept ............... c c c c
Smertestillende 
reseptfrie ............... c c c c
Sovemidler .......... c c c c
Beroligende  
medisiner .............. c c c c
Medisin mot 
depresjon .............. c c c c
12 Skriv ned alle medisiner – både de med og uten 
resept – som du har brukt regelmessig i siste 4 ukers 
periode. (Ikke regn med vitaminer, mineraler, urter, 
naturmedisin, andre kosttilskudd etc.)
VED FRAMMØTE vil du bli spurt om du har brukt 
antibiotika eller smertestillende medisiner de siste  
24 timene. Om du har det, vil vi be om at du oppgir 
preparat, styrke, dose og tidspunkt
13 Hvem bor du sammen med? (Sett kryss for hvert 
spørsmål og angi antall) 
Ja Nei Antall
Ektefelle/samboer ............................................. c c
Andre personer over 18 år ........................ c c
Personer under 18 år ...................................... c c
14 Kryss av for de slektninger som har eller har hatt
Foreldre Barn Søsken
Hjerteinfarkt .............................................. c c c
Hjerteinfarkt før fylte 60 år ......... c c c
Angina pectoris (hjertekrampe) ...... c c c
Hjerneslag/hjerneblødning .......... c c c
Beinskjørhet (osteoporose)  ................ c c c
Magesår/tolvfingertarmsår .......... c c c
Astma .............................................................. c c c
Diabetes ........................................................ c c c
Demens .......................................................... c c c
Psykiske plager ........................................ c c c
Rusproblemer ........................................... c c c
15 Har du nok venner som kan gi deg hjelp  
når du trenger det?
c Ja c Nei
16 Har du nok venner som du kan snakke fortrolig med?
c Ja c Nei
17 Hvor ofte tar du vanligvis del i foreningsvirksomhet 
som for eksempel syklubb, idrettslag, politiske lag, 
religiøse eller andre foreninger?
c Aldri, eller noen få ganger i året
c 1-2 ganger i måneden
c Omtrent 1 gang i uken
c Mer enn en gang i uken
ARBEID, TRYGD OG INNTEKT
18 Hva er din høyeste fullførte utdanning?  
(Sett ett kryss)
c Grunnskole, framhaldsskole eller folkehøyskole
c Yrkesfaglig videregående, yrkesskole eller realskole 
c Allmennfaglig videregående skole eller gymnas
c Høyskole eller universitet, mindre enn 4 år
c Høyskole eller universitet, 4 år eller mer
FAMILIE OG VENNERBRUK AV MEDISINER
Får du ikke plass til alle medisiner, bruk eget ark.
25 Hvor ofte driver du mosjon? (Med mosjon mener vi 
at du f.eks går en tur, går på ski, svømmer eller driver  
trening/idrett)
c Aldri
c Sjeldnere enn en gang i uken
c En gang i uken
c 2-3 ganger i uken
c omtrent hver dag
36 Hvor mange år til sammen har du røykt daglig?
Antall år
35 Hvor gammel var du da du begynte å røyke daglig?
Antall år
22 Arbeider du utendørs minst 25 % av tiden, eller i 
lokaler med lav temperatur, som for eksempel  
lager-/industrihaller?
c Ja c Nei
23 Hvis du er i lønnet eller ulønnet arbeid, hvordan vil 
du beskrive arbeidet ditt?
c For det meste stillesittende arbeid
(f.eks. skrivebordsarbeid, montering)
c Arbeid som krever at du går mye
(f.eks ekspeditørarbeid, lett industriarbeid, undervisning)
c Arbeid der du går og løfter mye
(f.eks postbud, pleier, bygningsarbeider)
c Tungt kroppsarbeid
24 Angi bevegelse og kroppslig anstrengelse i din  
fritid. Hvis aktiviteten varierer meget f eks mellom 
sommer og vinter, så ta et gjennomsnitt. Spørsmålet 
gjelder bare det siste året. (Sett kryss i den ruta som 
passer best)
c Leser, ser på fjernsyn eller annen stillesittende  
beskjeftigelse
c Spaserer, sykler eller beveger deg på annen måte 
minst 4 timer i uken (her skal du også regne med gang 
eller sykling til arbeidsstedet, søndagsturer med mer)
c Driver mosjonsidrett, tyngre hagearbeid, snømåking 
e.l. (merk at aktiviteten skal vare minst 4 timer i uka)
c Trener hardt eller driver konkurranseidrett  
regelmessig og flere ganger i uka
26  Hvor hardt mosjonerer du da i gjennomsnitt?
c Tar det rolig uten å bli andpusten eller svett.
c Tar det så hardt at jeg blir andpusten og svett
c Tar meg nesten helt ut
29 Hvor mange enheter alkohol (en øl, et glass vin, eller 
en drink) tar du vanligvis når du drikker?
c 1-2 c 5-6 c 10 eller flere
c 3-4 c 7-9
32 Har du røykt/røyker du daglig?
c Ja, nå c Ja, tidligere c Aldri
27 Hvor lenge holder du på hver gang i gjennomsnitt ?
c Mindre enn 15 minutter c 30 minutter – 1 time
c 15-29 minutter c Mer enn 1 time
30 Hvor ofte drikker du 6 eller flere enheter alkohol ved 
en anledning?
c aldri
c sjeldnere enn månedlig
c månedlig
c ukentlig
c daglig eller nesten daglig
28 Hvor ofte drikker du alkohol? 
c Aldri
c Månedlig eller sjeldnere
c 2-4 ganger hver måned
c 2-3 ganger pr. uke
c 4 eller flere ganger pr.uke
21 Hvor høy var husholdningens samlede bruttoinntekt 
siste år? Ta med alle inntekter fra arbeid, trygder, 
sosialhjelp og lignende.
c Under 125 000 kr c 401 000-550 000 kr
c 125 000-200 000 kr c 551 000-700 000 kr
c 201 000-300 000 kr c 701 000 -850 000 kr 
c 301 000-400 000 kr c Over 850 000 kr
34 Hvis du røyker daglig nå eller har røykt tidligere: 
Hvor mange sigaretter røyker eller røykte du vanlig-
vis daglig?
Antall sigaretter
33 Hvis du har røykt daglig tidligere, hvor lenge er det 
siden du sluttet?
Antall år 
31 Røyker du av og til, men ikke daglig?
c Ja c Nei
20 Mottar du noen av følgende ytelser?
c Alderstrygd, førtidspensjon (AFP) eller etterlattepensjon




c Dagpenger under arbeidsledighet
c Overgangstønad
c Sosialhjelp/-stønad 
37 Bruker du, eller har du brukt, snus eller skrå?
c Nei, aldri c Ja, av og til
c Ja, men jeg har sluttet c Ja, daglig
FYSISK AKTIVITET
ALKOHOL OG TOBAKK
48 Hvis du har født, fyll ut for hvert barn: fødselsår og 
vekt samt hvor mange måneder du ammet.  
(Angi så godt som du kan)









39 Hvor mange enheter frukt og grønnsaker spiser du i 
gjennomsnitt per dag? (Med enhet menes f.eks. en 
frukt, glass juice, potet, porsjon grønnsaker)
Antall enheter
38 Spiser du vanligvis frokost hver dag?
c Ja c Nei
40 Hvor mange ganger i uken spiser du varm middag? 
Antall
42 Hvor mye drikker du vanligvis av følgende?  















yoghurt .......................... c c c c c
Fruktjuice ...................... c c c c c
Brus/leskedrikker 
med sukker ................. c c c c c
44 Hvor ofte spiser du vanligvis fiskelever? 
(For eksempel i mølje)
c Sjelden/aldri c 1-3 g i året c 4-6 g i året





























45 Bruker du følgende kosttilskudd?
Daglig Iblant Nei
Tran, trankapsler ..................................................... c c c
Omega 3 kapsler (fiskeolje,selolje) ............ c c c
Kalktabletter ............................................................ c c c
47 Hvor mange barn har du født?
Antall
49 Har du i forbindelse med svangerskap hatt for høyt  
blodtrykk?
c Ja c Nei
52 Hvis Ja, i hvilket svangerskap?
c Første c Senere
53 Ble noen av disse barna født mer enn en måned for 
tidlig (før termin) pga. svangerskapsforgiftning?
c Ja c Nei
55 Hvor gammel var du da du fikk menstruasjon  
første gang?
Antall år
51 Har du i forbindelse med svangerskap hatt protein  
(eggehvite) i urinen?
c Ja c Nei
50 Hvis Ja, i hvilket svangerskap? 
c Første c Senere
54 Hvis Ja, hvilke(t) barn
Barn 1 Barn 2 Barn 3 Barn 4 Barn 5 Barn 6
c c c c c c
43 Hvor mange kopper kaffe og te drikker du daglig? 






56 Bruker du for tiden reseptpliktige legemidler som 
påvirker menstruasjonen?
P-pille, hormonspiral eller lignende .......c Ja c Nei
Hormonpreparat for overgangs-
alderen .............................................................................c Ja c Nei
46 Er du gravid nå?
c Ja c Nei c Usikker
VED FRAMMØTE vil du få utfyllende spørsmål om 
menstruasjon og eventuell bruk av hormoner. Skriv 
gjerne ned på et papir navn på hormonpreparater 
du har brukt, og ta det med deg. Du vil også bli 
spurt om din menstruasjon har opphørt og even-
tuelt når og hvorfor.
41 Hvor ofte spiser du vanligvis disse matvarene?
(Sett ett kryss pr linje)










Poteter ........................................ c c c c c
Pasta/ris ..................................... c c c c c
Kjøtt (ikke kvernet) ................ c c c c c
Kvernet kjøtt  
(pølser, hamburger o.l) ........... c c c c c
Grønnsaker, frukt, bær .. c c c c c
Mager fisk ............................... c c c c c
Feit fisk ....................................... c c c c c
(f.eks.laks, ørret, makrell, sild, kveite,uer)
KOSTHOLD SPØRSMÅL TIL KVINNER
    Appendix  I
e on  questionnaire of Tromsø 4 (Q )    

- en del av Tromsøundersøkelsen
SLIK FYLLER DU UT SKJEMAET:




Om du krysser feil, retter du ved å fylle boksen slik
Skriv tydelige tall  1 2 3 4 5 6 7 8 9 0
Riktig
Galt




1.6 For at du skal kunne vise oss hvor god eller 
dårlig din helsetilstand er, har vi laget en 
skala (nesten som et termometer), hvor den 
beste helsetilstanden du kan tenke deg er 
markert med 100 og den dårligste med 0. 
Vi ber om at du viser din helsetilstand ved 
å trekke ei linje fra boksen nedenfor til det 



















1. BESKRIVELSE AV DIN HELSETILSTAND
Vis hvilke utsagn som passer best på din 
helsetilstand i dag ved å sette ett kryss i en 
av rutene utenfor hver av de fem gruppene 
nedenfor:
1.03 Vanlige gjøremål (f.eks. arbeid, studier, 
husarbeid, familie- eller fritidsaktiviteter)
Jeg har ingen problemer med å utføre 
mine vanlige gjøremål
Jeg har litt problemer med å utføre mine 
vanlige gjøremål
Jeg er ute av stand til å utføre mine 
vanlige gjøremål
1.04 Smerte og ubehag
Jeg har verken smerte eller ubehag
Jeg har moderat smerte eller ubehag
Jeg har sterk smerte eller ubehag
1.01 Gange
Jeg har ingen problemer med å gå 
omkring
Jeg har litt problemer med å gå omkring
Jeg er sengeliggende
1.02 Personlig stell
Jeg har ingen problemer med personlig stell
Jeg har litt problemer med å vaske meg 
eller kle meg
Jeg er ute av stand til å vaske meg eller 
kle meg 
1.05 Angst og depresjon
Jeg er verken engstelig eller deprimert
Jeg er noe engstelig eller deprimert
Jeg er svært engstelig eller deprimert
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2.01 Hvor bodde du da du fylte 1 år?
I Tromsø (med dagens kommunegrenser)
I Troms, men ikke i Tromsø 
I Finnmark fylke
I Nordland fylke
Annet sted i Norge
I utlandet
2. OPPVEKST OG TILHØRIGHET




2.02 Hvordan var de økonomiske forhold i 





2.07 Hva var/er den høyeste fullførte utdanning til dine foreldre og din ektefelle/samboer? 




Grunnskole 7-10 år, framhaldsskole eller folkehøyskole ...........
Yrkesfaglig videregående, yrkesskole eller realskole  ....................
Allmennfaglig videregående skole eller gymnas .................................
Høyskole eller universitet (mindre enn 4 år) ............................................
Høyskole eller universitet (4 år eller mer) ...................................................
2.06 Lever din mor?
Ja Nei
Hvis NEI: hennes alder ved død .........
Lever din far?
Ja Nei
Hvis NEI: hans alder ved død...............
2.04 Hva regner du deg selv som? (Kryss av for 










3.03 Jeg opplever at yrket mitt har følgende sosiale status i samfunnet: (dersom du ikke er i arbeid nå, 






3.01 Nedenfor står tre utsagn om tilfredshet med livet som et hele. Deretter står to utsagn om syn på din 
egen helse. Vis hvor enig eller uenig du er i hver av påstandene ved å sette et kryss i rubrikken for 




enig 1 2 3 4 5 6 7
På de fl este måter er livet mitt nær idealet mitt ..............
Mine livsforhold er utmerkede ............................................................
Jeg er tilfreds med livet mitt ...................................................................
Jeg ser lyst på min framtidige helse ...............................................
Ved å leve sunt kan jeg forhindre alvorlige 
sykdommer .................................................................................................................
3.02 Nedenfor står fi re utsagn om syn på forhold ved din nåværende jobb, eller hvis du ikke er i 




enigArbeidet mitt er for belastende, fysisk eller 
følelsesmessig ..........................................................................................................
1 2 3 4 5 6 7
Jeg har tilstrekkelig innfl ytelse på når og hvordan 
arbeidet mitt skal utføres ...........................................................................
Jeg blir mobbet eller trakassert på 
arbeidsplassen min ............................................................................................
Jeg blir rettferdig behandlet på arbeidsplassen min ....
3. TRIVSEL OG LIVSFORHOLD








Blitt plaget psykisk, eller truet med vold  ................................
Blitt slått, sparket eller utsatt for annen type vold ........
Noen i nær familie har brukt rusmidler på en slik 
måte at dette har vært til bekymring for deg .....................
Dersom du har opplevd noen av disse forholdene, hvor mye plages du av dette nå?
Ingen plager Noen plager Store plager 
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4.01 Har du i løpet av den siste måneden følt deg 
syk eller hatt en skade?
Ja Nei
4. SYKDOMMER OG PLAGER
4.03 Blir du tungpustet i følgende situasjoner? 
(sett ett kryss for hvert spørsmål)
Ja Nei
Når du går hurtig på fl atmark eller 
svak oppoverbakke ....................................................
Når du spaserer i rolig tempo på 
fl atmark ...................................................................................
Når du vasker deg eller kler på deg ........
Når du er i hvile .............................................................
4.04 Hoster du omtrent daglig i perioder av året?
Ja Nei
Hvis JA: Er hosten vanligvis ledsaget av 
oppspytt?
Ja Nei
Har du hatt slik hoste så lenge som i en 3 
måneders periode i begge de to siste årene?
Ja Nei
4.02 Har du merket anfall med plutselig endring i 
pulsen eller hjerterytmen siste året?
Ja Nei
4.09 Nedenfor ber vi deg besvare noen spørsmål 
om din hukommelse: (sett ett kryss for hvert 
spørsmål)
Ja Nei
Synes du at din hukommelse har 
blitt dårligere? ..................................................................
Glemmer du ofte hvor du har lagt 
tingene dine? ....................................................................
Har du problemer med å fi nne 
vanlige ord i en samtale? ....................................
Har du fått problemer med daglige 
gjøremål som du mestret tidligere?.........
Har du vært undersøkt for 
sviktende hukommelse? .......................................
Hvis JA: har du i den samme perioden? 
(sett ett kryss for hver linje)
Ja Nei
Vært hos allmennlege/fastlege ....................
Vært hos spesialist.......................................................
Vært på legevakt ..........................................................
Vært innlagt i sykehus ............................................
Vært hos alternativ behandler 
(kiropraktor, homøopat eller lignende) ...........................
Hvis JA på minst ett av de fi re første spørs-
målene ovenfor: Er det et problem i hverdagen?
Ja Nei
4.05 Hvor ofte er du plaget av søvnløshet? 
(sett ett kryss)
Aldri, eller noen få ganger i året
1-3 ganger i måneden
Omtrent 1 gang i uka
Mer enn 1 gang i uka
Hvis du er plaget av søvnløshet månedlig 
eller oftere, når på året er du mest plaget? 





4.06 Har du i de siste par ukene hatt vansker 
med å sove?
Ikke i det hele tatt
Ikke mer enn vanlig
Heller mer enn vanlig
Mye mer enn vanlig
4.07 Har du de siste par ukene følt deg ulykkelig 
og nedtrykt (deprimert)?
Ikke i det hele tatt
Ikke mer enn vanlig
Heller mer enn vanlig
Mye mer enn vanlig
4.08 Har du i de siste par ukene følt deg ute av 
stand til å mestre dine vanskeligheter?
Ikke i det hele tatt
Ikke mer enn vanlig
Heller mer enn vanlig
Mye mer enn vanlig
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4.17 Hvis du har hatt smerter i eller ubehag fra 
magen siste året:
Ja Nei
Er disse lokalisert øverst i magen? ............
Har du hatt plagene så ofte som 1 dag 
i uka eller mer de siste 3 måneder? ........
Blir plagene bedre etter avføring? ............
Har plagene sammenheng med 
hyppigere eller sjeldnere avføring 
enn vanlig? ..........................................................................
Har plagene noen sammenheng med 
løsere eller fastere avføring enn vanlig? ...
Kommer plagene etter måltid? ....................
4.15 Har du opplevd ufrivillig barnløshet i mer 
enn 1 år?
Ja Nei
Hvis JA, skyldtes dette: Vet 
ikkeJa Nei
Forhold hos deg selv? ..............
Forhold hos partneren? ..........





4.19 Til kvinnen: Har du spontanabortert?
Ja Nei Vet ikke
Hvis JA, antall ganger ..............................
4.16 I hvilken grad har du hatt følgende plager i 






Vekslende treg mage 
og diare.......................................................
Oppblåsthet ..........................................
Smerter i magen .......................
4.20 Til mannen: Har din partner noen gang 
spontanabortert?
Ja Nei Vet ikke
Hvis JA, antall ganger ..............................
4.22 Har du fått stilt diagnosen Dermatitis 
Herpetiformis (DH)?
Ja Nei Vet ikke
4.21 Bruker du glutenfri diett?
Ja Nei Vet ikke
4.11 Har du vært plaget med smerter og/eller 
stivhet i muskler og ledd i løpet av de 









Øvre del av ryggen ....
Korsryggen ..........................
Hofter, ben, føtter .......
Andre steder ......................
4.10 Har du i løpet av det siste året vært plaget 
med smerter og/eller stivhet i muskler og 
ledd som har vart i minst 3 måneder sammen-









Øvre del av ryggen ....
Korsryggen ..........................
Hofter, ben, føtter .......
Andre steder ......................





4.18 Har du noen gang hatt: Alder 
siste gangJa Nei
Sår på magesekken .....................
Sår på tolvfi ngertarmen ......
Magesår-operasjon ..................4.13 Har du fått stilt diagnosen slitasjegikt av lege?
Ja Nei
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4.27 Hva slags hodepine er du plaget av?
Migrene Annen hodepine
4.28 Omtrent hvor mange dager per måned har 
du hodepine?
Mindre enn 1 dag
1-6 dager 
7-14 dager
Mer enn 14 dager
4.26 Har du vært plaget av hodepine det siste året?
Ja Nei
Hvis NEI, gå til del 5, kosthold
4.30 Hvor sterk er hodepinen vanligvis?
Mild (hemmer ikke aktivitet)
Moderat (hemmer aktivitet)
Sterk (forhindrer aktivitet)
4.31 Hvor lenge varer hodepinen vanligvis?
Mindre enn 4 timer
4 timer – 1 døgn
1-3 døgn
Mer enn 3 døgn
4.29 Er hodepinen vanligvis: 




Ensidig smerte (høyre eller venstre) ..................
4.33 Før eller under hodepinen, kan du da ha 
forbigående:
Ja Nei
Synsforstyrrelse? (takkede linjer, fl imring, 
tåkesyn, lysglimt) ...................................................................
Nummenhet i halve ansiktet eller i 
hånden? ...................................................................................
Forverring ved moderat fysisk aktivitet 
Kvalme og /eller oppkast .....................................
4.34 Angi hvor mange dager du har vært borte 
fra arbeid eller skole siste måned på grunn 
av hodepine: 
Antall dager ......................................................................
4.32 Dersom du er plaget av hodepine, når på året 





4.23 Har du fått stilt diagnosen cøliaki på 
bakgrunn av en vevsprøve fra tynntarmen 
tatt under en undersøkelse der du svelget 
en slange (gastroskopi)?
Ja Nei Vet ikke
4.24 Har du egne tenner? 
Ja Nei
4.25 Hvor mange amalgamfyllinger har du/har 
du hatt?
0 1-5 6-10 10+
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5. KOSTHOLD








3 g per uke
Ferskvannsfi sk (ikke oppdrett) .........................................................................
Saltvannsfi sk (ikke oppdrett) ..............................................................................
Oppdrettsfi sk (laks, røye, ørret) .......................................................................
Tunfi sk (fersk eller hermetisert) ..........................................................................
Fiskepålegg ......................................................................................................................
Skjell ........................................................................................................................................
Den brune innmaten i krabbe ...................................................................
Hvalkjøtt/sel/kobbekjøtt .................................................................................
Innmat fra rein eller elg .....................................................................................
Innmat fra rype ...........................................................................................................
5.02 Hvor mange ganger i året spiser du/spiste du vanligvis følgende? (antall ganger)
Som voksen I din barndom
Mølje (Antall ganger i året) .........................................................................................................................
Måsegg (Antall egg i året) ..........................................................................................................................
Reinsdyrkjøtt (Antall ganger i året) ....................................................................................................
Selvplukket sopp og bær (blåbær/tyttebær/multe) (Antall ganger i året) ........
5.03 Hvor mange ganger i måneden spiser du 
hermetiske matvarer (fra metallbokser)?
Antall ...........................................................................................
5.04 Bruker du vitaminer og/eller mineraltilskudd?
Ja, daglig Iblant Aldri


























3 g. per dag 
eller mer
5.06 Hvis du spiser sjokolade, hvor mye pleier du vanligvis å spise hver gang?
Tenk deg størrelsen på en Kvikk- Lunsj sjokolade, og oppgi hvor mye du spiser i forhold til den.





8.01 Hvor mange timer i uka driver du med 
følgende fritids- eller yrkesaktiviteter: 
Bilreparasjoner/lakkering, keramikkarbeid, 
maling/lakkering/løsemidler, frisør, glassmester, 
elektriker (Sett 0 om du ikke driver med slike 
fritids eller yrkesaktiviteter)
Antall timer per uke i gjennomsnitt .........
8.02 Bruker du hårfargemidler?
Ja Nei
Hvis JA, hvor mange ganger per år? ..
7.01 Har du ufrivillig gått ned i vekt siste  6 
måneder?
Ja Nei
Hvis JA: Hvor mange kilo? ....................
7.03 Er du fornøyd med vekta di nå?
Ja Nei
7.02 Anslå din vekt da du var 25 år gammel:
Antall hele kg ..............................................








6.02 Har du eller andre noen gang blitt skadet på grunn av at du har 
drukket? .................................................................................................................................................................
Har en slektning, venn, lege, eller annet helsepersonell vært 







6.01 Hvor ofte har du det siste året:
Aldri Månedlig Ukentlig
Ikke klart å stoppe og drikke alkohol når 
du først har begynt? ..............................................................
Ikke klart å gjøre det som normalt 
forventes av deg fordi du har drukket? ..........
Trengt en drink om morgenen for å få 
komme i gang etter en rangel? ....................................
Følt skyld eller anger etter at du har 
drukket? ...............................................................................................
Ikke klart å huske hva som skjedde kvelden 
før på grunn av at du hadde drukket? .............
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9.09 Alt i alt, har du opplevd at det er vanskelig 







9. BRUK AV HELSETJENESTER
9.01 Har du noen gang opplevd at sykdom er blitt 
mangelfullt undersøkt eller behandlet, og at 
dette har gitt alvorlige følger?
Ja, det har rammet meg selv 
Ja, det har rammet en nær pårørende 
(barn, foreldre, ektefelle/samboer)
Nei
Hvis JA, hvor mener du årsaken ligger? 





hos annet helsepersonell 
hos alternativ behandler
hos fl ere på grunn av svikt i rutiner og 
samarbeid
9.03 Har du noen gang klaget på behandling 
du har fått?
Har aldri vært aktuelt
Har vurdert å klage, men ikke gjort det
Har klaget muntlig
Har klaget skriftlig 
9.04 Hvor lenge har du hatt din nåværende 
fastlege/annen lege?
Mindre enn 6 måneder
6 til 12 måneder
12 til 24 måneder
Mer enn 2 år
9.02 Har du noen gang følt deg overtalt til å 
godta undersøkelse eller behandling som du 
selv ikke ønsket? 
Ja Nei
Hvis JA, mener du dette har hatt uheldige 
helsemessige følger?
Ja Nei
9.05 Ved siste legebesøk hos fastlegen, snakket 
legen(e) til deg slik at du forsto dem? Svar på 
en skala fra 0 til 10, hvor 0=de var vanskelige 
å forstå og 10=de var alltid enkle å forstå
0 1 2 3 4 5 6 7 8 9 10
9.06 Hvordan vil du karakterisere behandlingen 
eller rådgivingen du fi kk siste gang du var 
hos lege? Svar på en skala fra 0 til 10,  hvor 
0= meget dårlig behandling og 10 = meget 
god behandling
0 1 2 3 4 5 6 7 8 9 10
9.07 Har du i løpet av de siste 12 måneder 
opplevd at det har vært vanskelig å bli 
henvist til spesielle undersøkelser (som 
røntgen eller liknende) eller til spesialist-
helsetjenesten (privatpraktiserende 





9.08 Har du i løpet av de siste 12 måneder 
opplevd at det er vanskelig å bli henvist til 






9.13 Har du i løpet av de siste 12 måneder brukt 
urtemedisin , naturmidler eller naturlegemidler?
Ja Nei
9.10 Har du i løpet av de siste 12 måneder vært til 
undersøkelse eller behandling i spesialist-
helsetjenesten?
Ja Nei
9.14 Har du i løpet av de siste 12 måneder brukt 
meditasjon, yoga, qi gong eller thai chi som 
egenbehandling?  
Ja Nei
9.12 Har du noen gang før 2002 gjennomgått 
en operasjon på sykehus eller spesialist-
klinikk?
Ja Nei
9.11 Hvordan vil du karakterisere behandlingen 
eller rådgivningen du fi kk siste gang du var 
hos spesialist? Svar på en skala fra 0 til 10, 
hvor 0=meget dårlig og 10=meget god
0 1 2 3 4 5 6 7 8 9 10
Hvis JA, snakket legen(e) til deg slik at du 
forstod dem? Svar på en skala fra 0 til 10, hvor 
0=de var vanskelige å forstå og 10=de var alltid 
enkle å forstå
0 1 2 3 4 5 6 7 8 9 10
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10. BRUK AV ANTIBIOTIKA
10.01 Har du brukt antibiotika i løpet av de siste 12 måneder? (all penicillinliknende medisin i form av 
tabletter, mikstur eller sprøyter)
Ja Nei Husker ikke
Hvis JA, hva fi kk du behandling mot? Har du tatt 
fl ere antibiotikakurer, sett ett kryss for hver kur. Kur 1 Kur 2 Kur 3 Kur 4 Kur 5 Kur 6
· Urinveisinfeksjon (blærebetennelse, blærekatarr) .....................
· Luftveisinfeksjon (øre-, bihule- hals- eller lungebetennelse, 
bronkitt).....................................................................................................................
· Annet .....................................................................................................................
Antall dagers antibiotika kur ...................................................................
Hvordan skaffet du deg antibiotikakuren? Har du tatt 
fl ere kurer, sett ett kryss for hver kur.
Etter resept fra lege/tannlege ....................................................................
Uten kontakt med lege/uten resept:
· Kjøp direkte fra apotek i utlandet .............................................
· Kjøp gjennom Internett ........................................................................
· Rest fra tidligere kur tilgjengelig hjemme ........................
· Fått av familie/venner ............................................................................
· Andre måter .......................................................................................................
10.02 Har du antibiotika hjemme?  
Ja Nei
10.03 Kan du tenke deg å bruke antibiotika uten å 
kontakte lege først?
Ja Nei
Hvis JA, er dette etter avtale med lege for 
å behandle kronisk eller hyppig tilbake-
vendende sykdom?
Ja Nei
Hvis Nei, hvordan skaffet du deg dette 
legemiddelet? (Flere kryss er mulig)
Kjøpt direkte fra apotek i utlandet ...................
Kjøpt over Internett ...........................................................
Rest fra tidligere kur .........................................................
Fått av familie/venner ....................................................
Andre måter ...............................................................................
Hvis JA, hvilke tilstander vil du i så fall 














Da går jeg til sengs klokken ........................................................................................................................................................
Jeg gjør meg klar til å sove klokken ...................................................................................................................................
Antall minutter jeg trenger på å sovne ..............................................................................................................................................
Jeg våkner klokken ................................................................................................................................................................................
Ved hjelp av: Vekkeklokke annen ytre påvirkning (støy, familie etc) av meg selv
Antall minutter jeg trenger på å stå opp ..........................................................................................................................................
Da går jeg til sengs klokken ........................................................................................................................................................
Jeg gjør meg klar til å sove klokken ...................................................................................................................................
Antall minutter jeg trenger på å sovne ..............................................................................................................................................
Jeg våkner klokken ................................................................................................................................................................................
Ved hjelp av: Vekkeklokke annen ytre påvirkning ( støy, familie etc) av meg selv
Antall minutter jeg trenger på å stå opp ..........................................................................................................................................
11.02 Antall dager i løpet av uken hvor du ikke kan velge fritt når du vil sove (f.eks arbeidsdager)?
0 1 2 3 4 5 6 7
Vi vil stille deg noen spørsmål  som handler om dine søvnvaner. 
11.03 Antall dager i løpet av uken hvor du fritt kan velge når du vil sove (f.eks helger eller fridager)
0 1 2 3 4 5 6 7
11.01 Har du hatt skiftarbeid de tre siste månedene?
Ja Nei
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12.07 Har du tilbakevendende store kviser/
verkebyller som er ømme/smertefulle 
og som ofte tilheler med arr på følgende 








Hvis JA, hvor mange ganger i gjennomsnitt 
per år fi kk du antibiotika i den perioden du 
var mest plaget (sett ett kryss)
1-2 3-4 Mer enn 4 ganger
12.05 Har du ofte eller bestandig noen av 
følgende plager? (sett ett kryss for hver linje)
Ja Nei
Hevelse i ankler og legger, særlig 
om kvelden ........................................................................
Åreknuter ............................................................................
Eksem (rødt, kløende utslett) på 
leggene ..................................................................................
Smerter i beina når du går, men 
som forsvinner når du står stille ................
12.04 Har du eller har du noen gang hatt følgende 
hudlidelser? (sett ett kryss for hver linje)
Ja Nei
Psoriasis ...................................................................................
Atopisk eksem (barneeksem) .........................
Tilbakevendende håndeksem .........................
Tilbakevendende kviser over fl ere 
måneder ..................................................................................
Legg- eller fotsår som ikke ville gro i 
løpet av 3-4 uker ..........................................................
12. HUD OG HUDSYKDOMMER
Hvis JA på spørsmål om legg-og/eller fotsår, 
har du leggsår i dag?
Ja Nei
12.03 Har du noen gang fått antibiotikakur 
(penicillin og liknende medisin) på grunn 
av en hudlidelse, for eksempel betent 
eksem, kviser, leggsår som ikke vil gro, 
tilbakevendende verkebyll? 
Ja Nei
12.01 Hvor ofte dusjer eller bader du vanligvis? 
(sett ett kryss)
2 eller fl ere ganger daglig
1 gang daglig
4-6 ganger per uke
2-3 ganger per uke
1 gang per uke
sjeldnere enn 1 gang per uke
12.02 Hvor ofte vasker du vanligvis hendene med 





Mer enn 20 ganger
12.06 Har du noen gang fått følgende diagnoser 





Hvis JA, fi kk du da noen av følgende 





Større kirurgisk inngrep med 
fjerning av hud ..............................................................
Kirurgisk laserbehandling ..................................





De neste sidene med spørsmål skal ikke besvares av alle. Dersom du har svart ja på ett eller fl ere av 
spørsmålene under, ber vi deg om å gå videre til oppfølgingsspørsmål om emnet eller emnene du 
har svart ja på. De fi re første emnene er fra det første spørreskjemaet og det siste spørsmålet er fra 
dette skjemaet.
Vi har for enkelhetsskyld markert emnene med ulike farger slik at du lett skal fi nne frem til de spørs-
målene som gjelder for deg. 
Dersom du svarte JA på at du har: langvarige eller stadig tilbakevendende smerter som har vart i 3 
måneder eller mer, ber vi deg svare på spørsmålene på side 19 og 20. Margen er markert med grønn.
Dersom du svarte JA på at du har gjennomgått noen form for operasjon i løpet av de siste 3 årene, 
ber vi deg svare på spørsmålene på side 21 og 22. Margen er markert med lilla.
Dersom du svarte JA på at du arbeider utendørs minst 25% av tiden, eller i lokaler med lav 
temperatur, som for eksempel lager/industrihaller, ber vi deg svare på spørsmålene på side 23. 
Margen er markert med rød.
Dersom du svarte JA på at du har brukt reseptfrie smertestillende medisiner, ber vi deg svare på 
spørsmålene på side 24. Margen er markert med orange.
Dersom du svarte JA på at du har eller noen gang har hatt plager med hud (som psoriasis, atopisk 
eksem, legg- eller fotsår som ikke vil gro, tilbakevendende håndeksem, kviser eller verkebyll), ber vi 
deg svare på spørsmålene på side 25. Margen er markert med gul.
Har du svart NEI på disse fem spørsmålene, er du ferdig med besvarelsen din. Spørreskjemaet 
returneres i svarkonvolutten du fi kk utlevert på undersøkelsen. Portoen er allerede betalt. 
Skulle du ønske å gi oss en skriftlig tilbakemelding om enten spørreskjema eller Tromsøundersøkelsen 
generelt, er du hjertelig velkommen til det på side 26.
Har du noen spørsmål, kan du ta kontakt med oss på telefon eller på e-post. Du fi nner kontakt-
informasjon på baksiden av skjemaet. TUSEN TAKK for at du tok deg tid til undersøkelsen og 
til å svare på spørsmålene fra oss.
INFORMASJON TIL OPPFØLGINGSSPØRSMÅL
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13.01 Hvor lenge har du hatt disse smertene?
Antall år ............. måneder ............










13.02 Hvor ofte har du vanligvis disse smertene?
Hver dag En eller fl ere ganger i måneden
En eller fl ere ganger i uken Sjeldnere enn 1 gang i måneden
13.05 Hvilke former for behandling har du fått for smertene? (Kryss av for alle typer 
smertebehandling du har mottatt)
Ingen behandling Smerteskole/avspenning/psykoterapi
Smertestillende medisiner Akupunktur
Fysioterapi/kiropraktikk Alternativ behandling (homøopati, healing, 
aromaterapi, m.m.)Behandling ved smerteklinikk
Operasjon Annen behandling
Du svarte i det første spørreskjemaet at du har langvarige eller stadig tilbakevendende smerter som 
har vart i 3 måneder eller mer. Her ber vi deg beskrive de smertene litt nærmere.
13. OPPFØLGINGSSPØRSMÅL OM SMERTE 
13.04 Hva mener du er årsaken til smertene? (Kryss av for alle kjente årsaker)
Ulykke/akutt skade Fibromyalgi
Langvarig belastning Angina pectoris (hjertekrampe)





Leddgikt Annen årsak (beskriv under)




13.06 På en skala fra 0 til 10, der 0 tilsvarer ingen smerte og 10 tilsvarer den verst tenkelige smerten 




å få soveI hvor stor grad påvirker smertene 
søvnen din? ...................................................................





I hvor stor grad hindrer smertene 
deg i å utføre vanlige aktiviteter 
hjemme og i arbeid? ............................................





smerteHvor sterke er smertene når de er på 
sitt sterkeste? ..................................................................





smerteHvor sterke vil du si at smertene 
vanligvis er? ...................................................................
0 1 2 3 4 5 6 7 8 9 10
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14. OPPFØLGINGSSPØRSMÅL OM OPERASJON
I det første spørreskjemaet svarte du at du har gjennomgått en operasjon i løpet av de siste 3 
årene.
Nedenfor ber vi deg beskrive operasjonen. Dersom du har gjennomgått fl ere operasjoner i løpet 
av de siste 3 årene gjelder disse spørsmålene den siste operasjonen du gjennomgikk.
14.02 Hvor i kroppen ble du operert? (Dersom du 
samtidig ble operert fl ere steder i kroppen, 




























14.03 Bakgrunn for operasjonen:
Akutt sykdom/skade ........................................................
Planlagt ikke-kosmetisk operasjon ...................
Planlagt kosmetisk operasjon .................................
14.04 Hvor ble du operert?
Sykehuset i Tromsø ................................................................
Sykehuset i Harstad ...........................................................
Annet offentlig sykehus ................................................
Privat klinikk ...............................................................................
14.01 Hvor mange operasjoner har du totalt gjennomgått de siste 3 årene?
Antall ..............................................................................................................................................................................
14.05 Hvor lenge er det siden du gjennomgikk 
operasjonen?
Antall år ........... måneder ..........
14.06 Har du nedsatt følsomhet i et område nær 
operasjonsarret?
Ja Nei
14.07 Er du overfølsom for berøring, varme eller 
kulde i et område nær operasjonsarret? 
Ja Nei
14.08 Kan lett berøring av klær, dusj og lignende 
fremkalle ubehag/smerte? 
Ja Nei
14.09 Hvis du hadde smerter på operasjonsstedet 










smerteHvor sterke smerter hadde du fra 
operasjonsstedet før operasjonen ........





smerteHvor sterke smerter har du vanligvis 
fra operasjonsstedet nå ....................................






Hvor sterke smerter har du nå fra 
operasjonsstedet når smertene er 
på det sterkeste .........................................................
0 1 2 3 4 5 6 7 8 9 10
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15.06 Har du i løpet av de siste 12 måneder vært 
involvert i ulykke som krevde medisinsk 




15.02 Hvor lenge har du vært utsatt for kalde 
omgivelser under 0°C sist vinter?
Fritid/hobby (timer/uke) ...........................................
Arbeid (timer/uke) ...........................................................
Utendørs, godt kledd (timer/uke) ..................
Utendørs, tynnkledd (timer/uke) ....................
Innendørs, uten oppvarming (timer/uke) ...
I kalde omgivelser, med våte klær 
(timer/uke) ................................................................................
Kontakt med kalde gjenstander/
verktøy (timer/uke) .........................................................
15. OPPFØLGINGSSPØRSMÅL OM ARBEID I KALDT KLIMA
I det første spørreskjemaet svarte du ja på at du arbeidet i kaldt klima. Her er noen oppfølgings-
spørsmål vi håper du vil svare på.




15.05 Har du opplevd kløe og/eller utslett i 
forbindelse med kulde?
Ja Nei
15.07 Opplever du noen av følgende symptomer 
mens du oppholder deg i kalde omgivelser? 
I så fall, ved hvilken temperatur oppstår 
symptomene?
Ja Nei Under °C
Pusteproblemer ...............................
Pipende pust .......................................
Slim fra lungene ..............................
Brystsmerter ........................................
Forstyrrelse i hjerterytmen ..





Hvite fi ngre (kortvarig/
forbigående) ..............................................
Blå, blå-røde fi ngre 
(kortvarig/forbigående) .....................






Kontroll av bevegelse (for eksempel skjelving) .........................................................
Tungt fysisk arbeid..........................................................................................................................
Langvarig fysisk arbeid ..............................................................................................................
15.03 Hvilken omgivelsestemperatur 




Utføre andre aktiviteter utendørs ...
15.04 Har du hatt forfrysninger siste 12 måneder, 
med blemmer, sår eller skader i huden?
Ja Nei
Hvis JA, hvor mange ganger? .............
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16. BRUK AV RESEPTFRIE SMERTESTILLENDE LEGEMIDLER
Paracetamol: (Pamol, Panodil, Paracet, 
Paracetamol, Pinex)
Ikke brukt
Sjeldnere enn hver uke
Hver uke, men ikke daglig
Daglig
Hvor mye tar du vanligvis daglig 
når du bruker midlene? 
(Antall tabletter, stikkpiller) ......................................
16.01 Hvilke typer reseptfrie smertestillende 
legemidler har du brukt?
Ibuprofen: (Ibumetin, Ibuprofen, Ibuprox, Ibux)
Ikke brukt
Sjeldnere enn hver uke
Hver uke, men ikke daglig
Daglig
Hvor mye tar du vanligvis daglig 
når du bruker midlene? 
(Antall tabletter, stikkpiller) ......................................
Acetylsalisylsyre: (Aspirin,Dispril, Globoid)
Ikke brukt
Sjeldnere enn hver uke
Hver uke, men ikke daglig
Daglig
Hvor mye tar du vanligvis daglig 




Sjeldnere enn hver uke
Hver uke, men ikke daglig
Daglig
Hvor mye tar du vanligvis daglig 
når du bruker midlene? 
(Antall tabletter) ................................................................






16.02 Mot hvilke plager bruker du reseptfrie 








Fenazon med koffein: (Antineuralgica ,Fanalgin 
Fenazon-koffein, Fenazon-koffein sterke)
Ikke brukt
Sjeldnere enn hver uke
Hver uke, men ikke daglig
Daglig
Hvor mye tar du vanligvis daglig 
når du bruker midlene? 
(Antall tabletter) ................................................................
16.05 Kombinerer du behandlingen med bruk av 
reseptbelagte smertestillende midler?
Ja Nei
16.03 Mener du å ha opplevd bivirkninger av noen 






Fenazon med koffein .............................................
I det første spørreskjemaet svarte du at du hadde brukt reseptfrie smertestillende legemidler de 
siste 4 ukene. Her er noen oppfølgingsspørsmål vi håper du vil svare på.
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17. OPPFØLGINGSSPØRSMÅL OM HUDSYKDOMMER
På side 15 i dette spørreskjemaet svarte du at du har eller har hatt en hudsykdom. Her er noen 
oppfølgingsspørsmål vi håper du vil svare på.
17.08 Hvor gammel var du da du fi kk verkebyller 
første gang?
0-12 år 26-35 år
13-19 år 36-50 år  
20-25 år Over 50 år
17.07 Hvor mange utbrudd av verkebyller har du 
vanligvis i løpet av ett år? (sett ett kryss) 
0-1 4-6
2-3 Mer enn 6
17.09 Dersom du ikke lenger har verkebyller, hvor 
gammel var du da plagene forsvant?
0-12 år 26-35 år
13-19 år 36-50 år  
20-25 år Over 50 år
17.06 Her er en liste over faktorer som kan tenkes 
å utløse eller forverre verkebyller, kryss av 







Svar på en skala fra 0 til 10, der 0 tilsvarer ingen plager og 10 tilsvarer 




17.01 Psoriasis Ingen 
plager· Hvor mye plaget er du av din 
psoriasis i dag? .........................................................
0 1 2 3 4 5 6 7 8 9 10
· Hvor mye plaget er du av din 
psoriasis når den er som verst? .............
17.02 Atopisk eksem
· Hvor mye plaget er du av ditt 
atopiske eksem i dag? ..........................................
· Hvor mye plaget er du av ditt 
atopiske eksem når det er 
som verst? .....................................................................
17.03 Håndeksem
· Hvor mye plaget er du av ditt 
håndeksem i dag? ...................................................
· Hvor mye plaget er du av ditt 
håndeksem når det er som verst? ......
17.04 Kviser
· Hvor mye plaget er du av dine 
kviser i dag? ........................................................................
· Hvor mye plaget er du av dine 
kviser når de er som verst? ........................
17.05 Verkebyller
· Hvor mye plaget er du av dine 
verkebyller i dag? ..................................................
· Hvor mye plaget er du av dine 
verkebyller når de er som verst?..........
Skulle du ønske å gi oss en skriftlig tilbakemelding om enten spørreskjema eller 
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